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The interaction between circulating dietary constituents and the vascular endothelial 
m onolayer is vital to the proper maintenance o f  vascular hom eostatic mechanisms, 
such as vasoregulation. Endothelial dysfunction with subsequent loss o f  
vasoregulatory function are implicated in the early stages o f  atherosclerosis. 
Conjugated linoleic acid (C L A ) and hom ocysteine are dietary constituents that have 
been implicated in the aetiology o f  atherosclerosis.
C L A  is the collective term used for positional and geom etrical isomers deriving 
from the essential fatty acid, linoleic acid. Previous studies have indicated an 
atheroprotective effect o f  C L A , manifested in slow ing atherosclerotic plaque 
formation. C L A  m ay be eliciting these effects via  two potential mechanisms. Firstly, 
C L A  m ay be auto oxidised to several furan derivatives that possess a redox 
buffering capacity, and m ay modulate endothelium exposure to oxidative stress. 
Secondly, the influence o f  C L A  on the production o f  C yclooxygenase (Cox) derived 
eicosanoids, such as prostacyclin, has also been suggested as a possible m echanism 
o f  action. H om ocysteine is a sulphur-containing amino acid formed during the 
metabolism o f  methionine. Numerous studies have shown that 
hyperhom ocysteinem ia is an independent risk factor for atherosclerosis and 
atherothrombos. Prolonged exposure and high hom ocysteine concentrations result in 
impaired nitric oxide production and subsequent vascular endothelial dysfunction.
The objective o f  this study was to investigate whether both C L A  and/or 
hom ocysteine m odulate the expression and/or activity o f  two distinct vascular 
endothelial cell (EC ) components; Nitric oxide synthase (eN O S) and C ox. Both 
eN OS and C ox, responsible for production o f  nitric oxide and prostacyclin 
respectively, have been strongly implicated in the endothelial maintenance o f  
vascular hem odynam ic mechanisms.
The results from this study suggest that C L A  downregulates endothelial release o f  
prostacyclin (PG I2) and probably m any other prostanoids (PG E 2 and P G D 2) C L A  
isom er m ix does appear to putatively modulate prostanoid production and agonist- 
stimulated nitric oxide release from B A E C .
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Chapter 1 Introduction
1.1 Atherosclerosis
Atherosclerosis is a type o f  arteriosclerosis, and is the primary cause o f  all 
cardiovascular diseases. Atherosclerosis comes from the Greek words athero (meaning 
gruel or paste) and sclerosis (hardness). It is a type o f  pathogenic process in 
which deposits o f  fatty substances, cholesterol, cellular waste products, calcium and 
other substances build up beneath the endothelial layer o f  an artery. This build-up is 
called plaque. Plaques have various sizes and can be localized to areas o f  branching 
within the vasculature. Plaque build up is a natural process that occurs in everyone. The 
problem arises when people lead an “ unhealthy lifestyle” . Lack o f  exercise, a poor diet, 
smoking and drinking too much alcohol accelerates the process to a pathogenic level. 
Plaques can grow large enough to significantly reduce the blood's flow  through an 
artery. But most o f  the damage occurs when they become fragile and rupture. Plaques 
that rupture cause blood clots to form that can block blood flow  or break o ff  and travel 
to another part o f  the body. I f  either happens and blocks a blood vessel that supplies the 
heart, it causes a heart attack. I f  it blocks a blood vessel that supplies the brain, it causes 
a stroke. And i f  blood supply to the arms or legs is reduced, it can cause difficulty 
walking and eventually gangrene. Diagnosis o f  this disease is a problem. There are 
usually no symptoms until one or more arteries are so clogged with plaque that blood 
flow  is severely reduced, this makes an early diagnosis very difficult.
Cardiovascular disease (C V D ) is the major cause o f  death in the European Union. C V D  
causes 4 million deaths each year in Europe and over 1.5 million deaths each year in the 
European Union. Irish men and women have the highest rate o f  death before the age o f  
65 from coronary heart disease in the European Union. In 1993, 52 deaths per 100,000 
population compared to the EU  average o f  27. C V D  kills more Irish men and women o f  
all ages than any other disease.
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1.1.1 The molecular process of Atherosclerosis
Atherosclerosis is a slow, com plex disease that typically starts in childhood and often 
progresses when people grow  older. E xactly how atherosclerosis begins or what causes 
it isn't known, but some theories have been proposed. There is a com plex concert o f 
factors involved. The scientific consensus is that atherosclerosis begins when the 
vascular endothelium o f  the blood vessel becomes damaged. The three major causes o f 
damage to the arterial w all are; Elevated levels o f  cholesterol and triglyceride in the 
blood, hypertension and cigarette smoke.
F igu re  1 .1 .1  The formation and rupture o f  an atherogenic plaque
This damage causes activation o f  the vascular endothelium and initiation o f an 
inflammatoiy response. The endothelium w ill start to express adhesion molecules which 
attract and recruit blood leucocytes, macrophage and oxidised L D L  cholesterol (Fig.
1.1.1  A) (Li et al, 1993). The secretion o f  pro-inflammatory cytokines, which act as a 
chemotactic stimulus to the adherent leucocytes, direct their migration to the intima 
(M ach etal, 1999).
A
C
2
Inflammatory mediators act along with the expression o f  macrophage scavenger 
receptors, causing monocyte infdtration and accumulation in the arterial wall and 
subsequent transformation to foam cells after the uptake o f  modified lipoproteins, such 
as oxidatively modified LD L (O xLD L) (Quinn et al, 1987) (Rohrer et al, 1990). cells. 
In addition to M CP-1, macrophage colony-stimulating factor (M -CSF) contributes to 
the differentiation o f  the blood monocyte into the macrophage foam cell (Smith et al, 
1995) (Qiao et al, 1997). Inflammatory mediators produced in plaques can promote the 
replication o f  macrophages within the intima as well (Ross, 1999) (Fig. 1 .1.1, B). T 
lymphocytes join macrophages in the intima during lesion evolution. These leukocytes, 
as w ell as resident vascular wall cells, secrete cytokines and growth factors that can 
promote the migration o f  SM Cs to the intimal layer and cause subsequent proliferation 
(Ross, 1999).
Inflammatory processes not only promote initiation and evolution o f  atheroma, but also 
contribute to precipitating acute thrombotic complications o f  atheroma (Libby, 2001) 
(Fig. 1 .1.1C ). Most coronary arterial thrombi that cause fatal acute myocardial 
infarction arise because o f  a physical disruption o f  the atherosclerotic plaque. The 
activated macrophage abundant in atheroma can produce proteolytic enzymes capable 
o f  degrading the collagen that lends strength to the plaque’ s protective fibrous cap, 
rendering that cap thin, weak, and susceptible to rupture (Libby et al, 1996). y- 
Interferon arising from the activated T  lymphocytes in the plaque can halt collagen 
synthesis by SM Cs, limiting its capacity to renew the collagen that reinforces the plaque 
(Libby, 2001). Macrophages also produce tissue factor, the major procoagulant and 
trigger to thrombosis found in plaques. Inflammatory mediators regulate tissue factor 
expression by plaque macrophages, demonstrating an essential link between arterial 
inflammation and thrombosis (Libby and Simon, 2001).
3
1.1.2 The causes of Atherosclerosis
There are a number o f  w ell known risk factors that can accelerate this process towards a 
disease state. A  person may have an inherited genetic predisposition to certain diseases, 
but the major cause o f  atherosclerosis are environmental factors. The following is a 
brief summary o f  the major environmental risk factors for atherosclerosis:
Cholesterol: Cholesterol is a soft, fat-like substance. It is found in the blood and in all 
cells. There are two sources o f  Cholesterol in the body. The liver synthesizes it and it is 
ingested as part o f  the diet. It is used in the body to form cell membranes, some 
hormones and other tissues. Cholesterol and triglycerides are insoluble in blood and so 
they have to be transported to and from the cells by special “ carriers” called 
lipoproteins, which are synthesised by the liver and intestine. The three major forms o f  
lipoproteins are High Density Lipoprotein (HDL), Low  Density Lipoprotein (LDL) and 
V ery L ow  Density Lipoprotein (V LD L). It is the ratio o f  HDL to L D L  that is important 
in determining the risk cholesterol presents. Elevated LD L and low H DL levels are key 
risk factors for the development o f  atherosclerotic vascular disease (M iller et al, 1977; 
Sharrett et al, 1994). Large-scale clinical trials have shown that reducing LD L levels 
confers a substantial relative risk reduction for major cardiac events (Brown et al, 
1990).
Low-density lipoprotein (LDL) is retained in the intima, in part by binding to 
proteoglycan, and undergoes oxidative modification (Berliner et al, 1997; Williams and 
Tabas, 1998). Lipid hydro peroxides, lysophospholipids, carbonyl compounds, and 
other biologically active moieties localize in the lipid fraction o f  atheroma (Witztum 
and Berliner, 1998). These modified lipids can induce the expression o f  adhesion 
molecules, chemokines, pro inflammatory cytokines, and other mediators o f  
inflammation in macrophages and vascular wall cells (Witztum and Berliner, 1998).
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Hypertension: High blood pressure can develop because o f  two main factors, a genetic 
predisposition to hypertension, or it may be environmentally induced through a poor 
diet and lack o f  exercise. Blood pressure is the measure o f  the force o f  the blood 
pushing against the w alls o f  the arteries. When the heart contracts to pump out blood, 
pressure is highest. This measurement is called the systolic pressure. After pumping, the 
heart relaxes and pressure drops to its lowest point just before a new beat. This 
measurement is called the diastolic pressure. The measurement o f  an individual’s blood 
pressure is always expressed as systolic pressure over diastolic pressure. For example, 
normal blood pressure for adults is considered to be in the range o f  120/80 millimetres 
o f  mercury. Generally, blood pressure above 140/90 is considered to be high for adults, 
and blood pressure under 90/60 is considered to be too low.
Blood pressure levels are high in Ireland. Around 40% o f  men and women have raised 
blood pressure (more than 140/90mmHg) or are being treated for raised blood pressure. 
The prevalence o f  high blood pressure increases with age in both men and women. 
Around 85% o f  men and 80% o f  women with raised blood pressure are not receiving 
treatment. O f  those that are treated, just under two-thirds remain hypertensive.
Smoking'. Sm oking increases the risk o f  atherosclerosis by 50% and advances the 
natural history by ten years. Smoking is the strongest risk factor for premature 
atherosclerosis Wilhelmsen, L., 1988). Smoking is an especially powerful risk factor for 
peripheral vascular disease (De Cesaris, R. et al, 1992). Atherosclerosis is promoted by 
smoking thorough several means. Smoking directly damages the endothelium, increases 
vascular tone, increases platelet activation and promotes LD L oxidation. (Carlson, 
1979; Muscat, et al, 1991).
These are the main risk factors for cardiovascular disease, others include plasma levels 
o f  homocysteine, diabetes mellitus, obesity, physical inactivity and alcohol abuse. Diet 
has a major bearing on many o f  these risk factors. A  healthy diet can greatly reduce the 
risk posed by these factors (Hu and Willett, 2002).
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1.1.3 Atherosclerosis and the Diet
The relationship between diet and coronary heart disease has been studied intensively 
for nearly a century. In 1908, Ignatowski produced atherosclerosis in rabbits with a diet 
high in cholesterol and saturated fat (Antischkow, 1967): feeding the rabbits cholesterol 
alone produced identical lesions. In the early 1950s, controlled feeding studies 
demonstrated that saturated fatty acids and, to a lesser extent, cholesterol increased 
serum cholesterol concentration in humans (M cGill, 1979). Meanwhile, 
epidemiological studies found that increased serum cholesterol predicted risk o f 
coronary heart disease in human populations (Kato et al, 1973). These discoveries led to 
the classic diet-heart hypothesis, which postulated a primary role o f  dietary saturated fat 
and cholesterol in the cause o f  atherosclerosis and coronary heart disease in humans 
(Gordon, 1988). The diet heart hypothesis gained further support from ecological 
correlations relating saturated fat intake to rates o f  coronary heart disease in cohorts 
from different countries (Keys, 1980) and from studies o f  migrants from low- to high- 
risk countries (Kato et al, 1973).
Until recently, most epidemiological and clinical investigations o f  diet and coronary 
heart disease have been dominated by the diet-heart hypothesis. However, the original 
hypothesis was overly simplistic because the effects o f  diet on coronary heart disease 
can be mediated through multiple biological pathways other than serum total cholesterol 
or low-density lipoprotein cholesterol. Other factors implicated in heart disease include 
Lipid levels, Blood Pressure, Thrombotic Tendency, Cardiac Rhythm, Endothelial 
Function, System ic Inflammation, Insulin Sensitivity, Oxidative Stress and 
Homocysteine Levels (Hu et al, 2002). The existence o f  these multiple pathways 
heightens the need to study clinical outcomes because the use o f  a single intermediate 
end point as a surrogate o f  coronary heart disease risk could be misleading. In the past 2 
decades, understanding o f  the nutrients and foods likely to promote cardiac health has 
grown substantially ow ing to studies o f  the molecular mechanisms o f  atherosclerosis 
and the metabolic effects o f  various nutrients and foods, large and carefully conducted 
prospective cohort investigations, and dietary intervention trials. Although the search 
for the optimal diet for prevention o f  coronary heart disease is far from over, more 
specific and firmer evidence on diet and coronary heart disease is now available.
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1.1.4 The Vascular Endothelium
Endothelial cell structure and functional integrity are important in the maintenance o f 
the vessel wall and circulatory function (Lusher, 1990). A s a barrier, the endothelium is 
semi-permeable and controls the transfer o f  small and large molecules (Charo et al,
1998). However, endothelial cells are dynamic and are capable o f  conducting a variety 
o f  metabolic and synthetic functions. These cells exert significant paracrine and 
endocrine actions through their influence on the underlying smooth muscle cells or on 
circulating blood elements, such as platelets and white blood cells (Diodati et al, 1998). 
Under basal conditions endothelial cells are intimately involved in maintaining the 
nonthrombogenic blood-tissue interface by regulating thrombosis, thrombolysis, 
platelet adherence, vascular tone and blood flow. They produce and release a variety o f  
vasoactive substances, such as prostacyclin (Bunting et al, 1976) and nitric oxide 
(Ramsey et al, 1993) both o f  which inhibit platelet aggregation and cause vasodilation. 
These mediators are released in response to a range o f  chemical stimuli, such as 
thrombin, bradykinin, or AD P, as w ell as changes in haemodynamic forces, such as 
alterations in blood pressure or flow  (Sumpio, 1993).
The myriad o f  functions o f  the endothelial cell makes the endothelium indispensable for 
body homeostasis, as is evident in its many finely controlled mechanisms. However, 
discordant stimulation o f  endothelial cells or an uncontrolled endothelial cell response 
are common events in many pathologic processes including atherosclerosis and diabetes 
(De Caterina, 2000). These diseases are related to endothelial injury, dysfunction and 
activation. Disturbed endothelial function plays a large role in cardiovascular disease 
(Drexler and Zeiher, 1991; Zeiher et al, 1991).
Nitric oxide synthase and cyclooxygenase are enzymatic pathways that are essential to 
the homeostatic function o f  the vascular endothelium (Drexler, 1999; Davidge, 1999). 
The production o f  nitric oxide and prostaglandin’ s are necessary for the regulation o f  
platelet adherence, vascular tone and blood flow  (Charo et al, 1998). The following 
sections review both enzymatic pathways and their importance to vascular function.
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1.1.5 Endothelial Nitric Oxide Synthase (eNOS)
Nitric oxide is a potent vasodilatory gas in the cardiovascular system generated by the 
nitric oxide synthase (NOS) family o f  proteins (M ayer and Hemmens, 1997). N OS is 
N AD PH  dependent haem containing oxido-reductases that convert one o f  the guanidino 
nitrogen’ s o f  L-arginine to nitric oxide and the by product L-citrulline. There are three 
distinct N O S isoforms exist in mammalian cells: neuronal (nNOS), inducible (iNOS) 
and endothelial (eNOS) (Stuehr, 1997). eNOS and nNOS are generally referred to as 
constitutively expressed, Ca2+ -dependent enzymes, although eNOS can also be 
activated in a Ca2+ -independent manner (Ayajiki et al, 1997). Inducible N OS is 
expressed at high levels only after induction by cytokines or other inflammatory agents, 
and its activity is dependent on an increase in Ca2+. A ll N O Ss have approximately 60% 
the same amino acid identity and very similar primary structures.
Suw>r.i i
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F igu re 1 .1.4 .1  Scheme o f  the domain structure o f  the N O S dimer, showing cofactor and 
substrate binding sites
The enzyme functions as a dimer consisting o f  two identical monomers, which can be 
functionally (and structurally) divided into two major domains: a C-terminal reductase 
domain, and an N-terminal oxygenase domain (Fig 1.1.4.1). The former contains 
binding sites for one molecule each o f  N AD PH , FAD , and FMN, in close homology 
with cytochrome P-450 reductase, whereas the latter binds haem and BH , as well as the 
substrate L-arginine. Between these two regions lies the calmodulin (CaM ) binding 
domain, which plays a key role in both the structure and function o f  the enzyme.
The sub cellular localisation o f  eNOS and changes in its cellular compartmentalisation 
follow ing cell stimulation are controversial. Reports have assigned eNOS to the golgi
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apparatus (O ’Brien et al, 1995), while others have localised eNOS in the plasma 
membranes at the plasmalemmal caveolae (Hecker et al, 1994). The truth lies 
somewhere in between as eNOS is associated with the plasma membrane and the 
perinuclear region, identified as the G olgi apparatus (Garcia-Cardena et al, 1996).
Biosynthesis o f  nitric oxide involves a two step oxidation o f  L-arginine to L-citrulline, 
with concomitant production o f  nitric oxide. The reaction consumes 1.5mol ofN A D P H , 
and 2 mol o f  oxygen per mol o f  L-citrulline formed. The proposed mechanisms involve 
an initial hydroxylation o f  L-arginine, which can also act as a substrate for NOS. This is 
followed by oxidation o f  the intermediate, using a single electron from N AD PH , to 
form L-citrulline and N O  (Griffith and Stuehr, 1995) (Fig. 1.1.4.2). The enzyme is also 
capable o f  catalysing the production o f  additional products, notably super oxide anion, 
depending on the conditions.
H
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F ig u r e  1.1.4.2 The NOS-catalysed reaction
Endothelium-derived nitric oxide is the most potent endogenous vasodilator known 
(Furchgott and Zaw adzki, 1980). Nitric oxide induces vasodilation by stimulating 
soluble guanylate cyclase to produce cG M P (Ignarro et al, 1984). Nitric oxide has a 
short half-life and avidly interacts with sulfhydryl-containing proteins, haem proteins, 
and oxygen-derived free radicals to produce nitrite and nitrate (Kim et al, 2001). By 
virtue o f  its ability to nitrosylate proteins, it may change their activity or behaviour. The 
physiological importance o f  this endothelium-derived vasodilator is reflected by the 
significant increase in vascular resistance that is induced in animals and humans
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exposed to pharmacological antagonists o f  nitric oxide synthase (Vallance et al, 1989; 
Rees et al, 1989). Endothelium-derived nitric oxide also inhibits platelet and leukocyte 
adherence to the vessel wall (Kubes et al, 1991; Tsao et al, 1994). This effect o f  nitric 
oxide is mediated in part by the activation o f  cGM P and phosphorylation o f  intracellular 
signalling proteins, such as vasodilator stimulated phosphoprotein (Smolenski et al,
1998). In addition, nitric oxide suppresses the expression o f  adhesion molecules and 
chemokines regulating endothelial interaction with circulating blood elements (Spiecker 
et al, 1998). Finally, endothelium-derived nitric oxide also inhibits vascular smooth 
muscle cell proliferation (Garg and Hassid, 1989). This is in part mediated by an effect 
o f  nitric oxide, an increase in vascular smooth muscle cell apoptosis (Weidinger et al, 
1990). In contrast, nitric oxide is a survival factor for endothelial cells (Dimmeler et al,
1997). These observations are consistent with the view  that nitric oxide is an 
endogenous antiatherogenic molecule. Impairment o f  endothelial N O S contributes to 
the pathological alterations in vascular reactivity and structure that are observed in 
atherosclerosis (Cooke and Dzau, 1997; Vanhoutte, 1997). Pharmacological inhibition 
or genetic deficiency o f  N O S inhibits endothelium-dependent vasodilation, impairs 
tissue blood flow , and raises the blood pressure (Cooke and Dzau, 1997) Furthermore, 
nitric oxide deficiency promotes the adherence and intimal accumulation o f 
mononuclear cells and accelerates lesion formation in animal models o f  atherosclerosis 
(Cooke and Dzau, 1997; Gimbrone et al, 1995). B y  contrast, enhancing nitric oxide 
production in the vessel wall slows or even reverses atherogenesis or restenosis (Cooke 
et al, 1992; Von der Leyen et al, 1995; Wang, B .Y . et al, 1999).
eNOS is a calcium/calmodulin-dependent enzyme: in vascular endothelial cells, eNOS 
is activated in response to the transient increases in intracellular calcium initiated by the 
activation o f  diverse G  protein-coupled receptors, including the bradykinin B2 receptor 
(Andrew and Mayer, 1999). eNOS is also activated by phosphorylation by protein 
kinase Akt, and eN OS is inhibited by the M A P kinases ERK1/2 (Bernier et al, 2000). 
eN OS phosphorylation by protein kinase Akt is promoted by vascular endothelial 
growth factor (Fulton et al, 1999; M ichell, et al, 1999), by fluid shear stress (Dimmeler 
et al, 1999; Gallis et al, 1999) and stretch.
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1.1.6 Cyclooxygenase I (Cox I)
Prostaglandin’s (PGs) and thromboxane (Tx) are critical modulators of vascular tone in 
both physiological and pathophysiological conditions (Davidge, 1999). The production 
of these eicosanoids is regulated by the availability of arachidonic acid and the activity 
of prostaglandin H synthase (PGHS), also known as cyclooxygenase (Cox) (Smith et al,
2000). Liberation of arachidonate from membrane phospholipids is mediated through 
phospholipases. Once arachidonate is released it is converted to PGH2 by Cox. Cox is a 
rate-limiting enzyme that exhibits a cyclooxygenase activity that incorporates two 
molecules of oxygen into arachidonic acid to form PGG2 and a peroxidase activity 
catalysing a 2 -electron reduction of PGG2 to PGH2. Cell-specific isomérisation or 
reduction of PGH2 produces biologically active end products, such as prostacyclin 
(PGI2) and thromboxane (Smith and Murphy, 2002). There are two known isoforms, 
Cox I and Cox II.
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Figure 1.1.6: Cyclooxygenase pathway. 
Arachidonate is converted to PGH2 by a 
cyclooxygenase activity and a peroxidase 
activity. Both the cyclooxygenase and 
peroxidase activities are associated with a 
single protein, Cyclooxygenase. Cell specific 
isomérisation or reduction of PGH2 results in 
the major biological prostanoids.
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Cyclooxygenase-I is a 69-kDa protein that is constitutively expressed but can also be 
induced. For example, shear stress induces expression o f  cyclooxygenase I protein in 
human umbilical vein endothelial cells (Doroudi et al, 2000). In addition, there are a 
number o f  putative promoter response elements for C ox I, including shear stress 
elements and transcription factor sites (Wang et al, 1993). Both the endothelium and 
smooth muscle cell contain Cox; however, endothelial cells contain up to 20 times more 
C ox than smooth muscle cells (DeW itt et al, 1983). In regard to sub cellular localization 
o f  C ox, immunogold-labeling microscopy has demonstrated that both C ox I and Cox II 
are present in equal proportions in the luminal surface o f  endoplasmic reticulum and in 
the inner and outer membranes o f  the nuclear envelope in human umbilical vein 
endothelial cells (Spencer et al, 1998). There does not appear to be a different sub 
cellular localization o f  C ox I versus C ox II.
Prostaglandin’s (Prostacyclin, Thromboxane) are formed by most cells in our bodies 
and act as autocrine and paracrine lipid mediators (Smith and Murphy, 2002). They are 
not stored but are synthesized de novo from membrane-released arachidonic acid when 
cells are activated by mechanical trauma or by specific cytokine, growth factor, and 
other stimuli (e.g., collagen and A D P  in platelets, bradykinin and thrombin in 
endothelium) (Davidge, 1999). Under normal physiological conditions, eicosanoids 
(primarily prostacyclin) produced by the cyclooxygenase pathway, primarily Cox I, 
generally induce vasorelaxation. However, in vascular pathologies, there may be an 
imbalance where PGHS-dependent vasoconstrictors become more predominant 
(Davidge, 1999).
Prostaglandin’ s are released from endothelial cells predominantly by facilitated 
transport through a known prostaglandin transporter (PGT) o f  the organic anion 
transporter polypeptide family, and potentially by other uncharacterised transporters 
(Schuster, 1998). Due to the evanescent nature o f  thromboxane and prostacyclin (which 
have half-lives on the order o f  seconds to a few minutes), these compounds must act 
near their sites o f  synthesis. There are at least 9 known prostaglandin receptor forms in 
mouse and man, as w ell as several additional splice variants with divergent carboxyl 
termini (Narumiya and Fitzgerald, 2001). Four o f  the receptor subtypes bind PGE2
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(EP1-EP4), two bind PGD2 (DPi and DP2) (Hirai el al, 2001) and the receptors that bind 
PGF2a, PGI2, and TxA2 (FP, IP, and TP, respectively) each derive from a single gene. 
The prostaglandin receptors belong to three clusters (on the basis of homology and 
signalling attributes rather than by ligand-binding properties) within a distinct subfamily 
of the G protein-coupled receptor (GPCR) super family of seven-transmembrane 
spanning proteins. The lone exception is DP2, which is a member of the chemoattractant 
receptor sub grouping. The "relaxant" receptors IP, DP), EP2, and EP4 form one cluster, 
signalling through Gs-mediated increases in intracellular cyclic adenosine 
monophosphate (cAMP); the "contractile" receptors EPi, FP, and TP form a second 
group that signals through Gq-mediated increases in intracellular calcium. The EP3 
receptor is regarded as an "inhibitory" receptor that couples to Gi and decreases cAMP 
formation. Although most of the prostaglandin GPCRs are localized at the plasma 
membrane, some are situated at the nuclear envelope (Bhattacharya et al, 1998).
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1.2 Conjugated Linoleic Acid (CLA)
Conjugated linoleic acid (C L A ) refers to a group o f  polyunsaturated fatty acids that 
exist as positional and stereo (cis, trans) isomers o f  conjugated dienoic octadecadienoate 
(18:2). The predominant geometric isomer in foods is the c9tl 1-C L A  isomer (Ma et al,
1999), also called rumenic acid, followed by t7,c9-CLA, c l l ,t l3 - C L A , c8,tlO -CLA and 
the t lO ,c l2 -C L A  isomer. The three-dimensional stereo-isomeric configuration o f  C L A  
may be in combinations o f  cis and/or trans configurations.
F igu re  1.2: Structures o f  trans-10,c is-12 C L A  (upper panel),cis-9,trans-11 C L A
(middle panel), and linoleic acid (lower panel)
A  number o f  physiological properties have been attributed to C L A  including action as 
an antiadipogenic, antidiabetogenic, anticarcinogenic as w ell as an antiatherosclerotic 
agent (Belury et al, 1997; Belury and Vanden Heuvel, 1997; Houseknecht et al, 1998). 
C L A  also has effects on bone formation (Li and Watkins, 1998) and the immune system 
as w ell as fatty acid and lipid metabolism and gene expression in numerous tissues. Any
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one o f  these effects would be considered advantageous, the possibility that C L A  affects 
all o f  these is fascinating. On top o f  this, the fact that the richest sources o f  C L A , meat 
and dairy products, are consumed by people worldwide has massive implications and 
public health.
1.2 .1 C L A  in the Diet
C L A  is found in foods such as beef and lamb, as well as dairy foods derived from these 
ruminant sources (Chin et al, 1992). The levels o f  C L A  in various foods have been 
reported to vary from as low  as 0.2mg per gram o f fat in corn and peanut oil to as high 
as 17m g per gram o f  beef or 30mg per gram o f  milk fat. Trace quantities have been 
found in seafood’ s and vegetable oils.
The C L A  in foods derived from ruminants relates to the bio hydration o f  unsaturated 
fatty acids by rumen bacteria (Bartlet and Chapman, 1961). M ost o f  the studies 
investigating the sources o f  ruminant C L A  have involved dairy cows and milk fat. The 
predominant isomer, representing 75-80% o f  total C L A , is cis-9, trans-11 C L A  (Kelper 
et al, 1966). This isomer is formed as an intermediate in the microbial bio 
hydrogenation o f  linoleic acid. The second most prevalent C L A  isomer in milk fat is 
trans-7, cis-9 and it originates almost exclusively from endogenous synthesis involving 
A 9-desatursae and trans-7 C l 8:1 produced in the rumen (Coral et al, 2002). M ilk fat 
content is largely dependent on rumen outflow o f  trans-11 C l 8:1 and tissue activity o f 
A 9-desaturase; both o f  these variables can be affected by diet and vary substantially 
among individuals. In a review paper by Parodi et al (1999) the early literature 
describing seasonal fluctuation o f  C L A  in cows milk is summarised. The amounts in 
spring and summer, when cows pastured, were substantially higher than in fall and 
winter, when cows were stall fed.
Because o f  various food types throughout the world containing different levels o f  C L A  
human dietary intakes o f  C L A  can differ substantially and because o f  the clear potential 
for various isomers o f  C L A  to influence human health, documentation o f  dietary C L A  
is o f  interest. Various methodologies have been utilized to quantify intake o f  C L A ,
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including the use o f  disappearance data, dietary recalls, food frequency questionnaires 
and biochemical analysis o f  food duplicates. Researchers utilizing indirect 
methodologies have estimated C L A  intakes in various locations including the United 
States, Australia, Germany and Finland to range from 50 to lOOOmg/day (Lichtenstein, 
A . H., 2000). Using food duplicate technology, considered the gold standard, total C L A  
intakes are reported to be between 212 and 151mg/day for men and women.
1.2.2 CLA and atherosclerosis
1.2.2.1 In vivo research 
There is a growing body o f  evidence that C L A  reduces atherosclerotic plaque formation 
in experimental animals. When C L A  (0.5g/rabbit/day) was added to a 
hypercholesterolemic diet and fed to rabbits for 12 weeks, serum triglycerides and low 
density lipoprotein cholesterol levels were significantly reduced compared with rabbits 
fed a diet without C L A  (Lee et al, 1994). Importantly for heart disease risk, aortas o f 
rabbits fed the CLA-containing diet exhibited less atherosclerotic plaque formation. In a 
subsequent study, hamsters were fed a diet with or without C L A  designed to induce 
hypercholesterolemia (Nicolosi et al, 1997). The diet with C L A  (1.0% ) reduced plasma 
total cholesterol, non-high density lipoprotein-cholesterol, and early aortic 
atherosclerosis relative to a diet with linoleate (Wilson et al, 2000). In a similar model 
in hamsters fed a hypercholesterolemic diet, c 9 tll-C L A , the sole C L A  isomer in the 
diet, had no effect on plasma lipids (Gavino, 2000). Because dietary C L A  was 
associated with significantly reduced formation o f  dienes, it was concluded that the 
ability o f  C L A  to reduce aortic plaque formation could be due to changes in low  density 
lipoprotein oxidative susceptibility. In contrast to protective effects o f  C L A  on 
atherosclerotic plaque formation in rabbits and hamsters, C L A  inducted the formation 
o f  aortic fatty acid streaks in C57Black/6 mice (inbred atherosclerotic inducible mouse 
model) fed an atherogenic diet (Munday et al, 1999), suggesting a possible species 
specific effect.
The effects o f  C L A  on thrombotic properties o f  blood cells have been studied in 
cultured platelets in vitro and in human subjects. In cultured platelets, C L A , c 9 tll-  
C L A , and t l0 c l2 -C L A  inhibited arachidonic acid-, or collagen-, induced platelet
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aggregation (Truitt et al, 1999). These findings were associated with reduced 
production o f  the proaggregatory cyclooxygenase products o f  14C-arachidonate, 14C- 
thomboxane-A2, and 14C-thromboxane-B2. In human subjects supplemented with C L A  
(3.9g/day) or placebo (sunflower oil) for 93 days, there were no differences in platelet 
aggregation or prothrombin time (Benito et al, 2001).
Because C L A  appears to exert differential effects on lipid profiles as well as 
atherogenic markers in various animal models, further work is needed to demonstrate 
the mechanisms by which C L A  may prevent atherosclerosis and to elucidate its role in 
modulating cardiovascular disease risk in humans.
1.2.2.2 In vitro research
There have been very few in vitro studies carried out to elucidate the cellular 
mechanisms by which C L A  exerts it anti-atherosclerotic effects. The decrease in LDL 
cholesterol observed in the animal studies mentioned above, is consistent with both 
decreased apolipoprotein B secretion, observed in Hep G2 cells (Yotsumoto et al,
1999), and decreased intracellular triacylglycerol, observed in mouse adipocytes (Park 
et al, 1999). With regard to atherogenesis specifically and effects on vascular cells, little 
has been published. It has been shown that C L A  affects arachidonic acid metabolism in 
human saphenous endothelial cells, inhibiting eicosanoid production (Urquhart et al,
2001) This suggests an anti-inflammatory action that may contribute to C L A s anti­
atherogenic properties.
1.2.2.3 Proposed mechanisms behind CLAs anti-atherosclerotic 
properties
There are a number o f  hypotheses to explain the mechanisms o f  action o f  CLA. 
Originally, C L A  w as thought to protect LD L from oxidation because it was a more 
potent anti oxidant than a-tocopherol (Ha et al, 1990). This theory was rejected though 
because it was found that C L A  could not effectively protect membranes from oxidative 
modification under conditions o f  metal ion-dependant oxidative stress (Van den Berg et
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al, 1995). Although C L A  may not function as a true antioxidant, it has been found that 
auto-oxidation o f  C L A  produced furan fatty acids, which may have the potential to 
protect against oxidant-mediated toxicity (Yuraw ecz et al, 1995).
C L A  is incorporated into cell membrane phospholipids (Ha et al, 1990). This gives rise 
to the possibility that it may m odify membrane fluidity and exert its effects by altering 
intracellular events like signal transduction pathways or eicosanoid synthesis. It has 
already been suggested that C L A  alters eicosanoid synthesis, competing with linoleic 
acid and inhibiting eicosanoid production (Urquhart et al, 2001). Another study 
suggests that various isomers o f  C L A  can be precursors for eicosanoid synthesis 
(Sebedio et al, 1997) as they are elongated and desaturated in a manner similar to 
linoleic acid. It thus seems possible that C L A  derived eicosanoids may be produced. 
This could affect a number o f  pathways involved in lipid metabolism. There is also the 
potential for C L A  to affect intracellular lipid metabolism. It has been shown that hepatic 
stearoyl coenzym e A  desaturase m R N A expression is decreased by C L A  (Lee et al,
1998), and that this down regulation is specific for the tlO, c l2  isomer (Choi, Y . et al,
2000). This enzyme is responsible for desaturating palmitic and stearic acids to 
palmitoleic and oleic acid, respectively.
A lso, it has been established that C L A  is both a ligand and an activator for the 
peroxisome proliferator-activated receptor a  (Moya-Camarena et al, 1999). This nuclear 
transcription factor modulates gene expression for several enzymes and proteins 
involved in lipid metabolism, including lipoprotein lipase (Schoonjans et al, 1996), fatty 
acid binding protein (Sterschele et al, 1994) and acyl coenzyme A  oxidase (Belury et al, 
1997). A lso  different C L A  isomers have different potencies for peroxisome proliferator- 
activated receptor a  (Moya-Camarena et al, 1999).
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Homocysteine (Hey) is a nonprotein-forming, thio-containing amino acid formed by 
déméthylation o f  methionine. It is metabolised by remethylation to methionine or by 
transsulfuration to cysteine.
1.3 Homocysteine
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F ig u re  1.3 Homocysteine metabolism. AdoH cy, S-adenosylhomocysteine; AdoMet,
S-adenosylmethionine; B6, vitamin B6 (pyridoxal phosphate); B12, 
vitamin B 12  (methylcobalamin); C BS, cystathionine b-synthase; M S, 
methionine synthase; M TH FR, methylenetetrahydrofolate reductase; 
THF, tetrahydrofolate.
The hypothesis that homocysteine is atherogenic was put forward more than 30 years 
ago by Kilm er M cC ully, who observed vascular lesions in children with inherited 
disorders o f  methionine metabolism (homocystinuria) (M cCully, 1969). Homocysteine 
is now considered by many as a major and independent risk factor for atherosclerotic 
vascular disease (Boers, 2000).
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1.3.1 Metabolism of Homocysteine
Homocystinuria is most commonly caused by a genetic deficiency for the enzyme 
cystathionine b-synthase (CbS). Individuals homozygous for this condition are unable 
to convert homocysteine to cystathionine, leading to high levels o f  circulating 
homocysteine, this in turn results in excretion o f  homocysteine in the urine. 
H om ozygosity for the enzyme methylenetetrahydrofolate reductase (M THFR) and, less 
commonly, methyltransferase deficiency also result in homocystinuria, causing skeletal 
and ocular defects and premature vascular events. Under normal conditions, 
homocysteine concentration is maintained at low levels by the enzymes CbS and 
M TH FR, and is removed from the body by remethylation to methionine, or trans- 
sulphuration to products that are cleared in the urine. Remethylation occurs by the 
action o f  the enzyme M TH FR with folate as a co-substrate, and by methionine synthase 
with vitamin B 12  as a co-factor. Trans- sulphuration requires CbS, which uses vitamin 
B6 as a cofactor. Normal levels o f  fasting plasma homocysteine are considered to be 
between 5 and 15 pM. Moderate, intermediate and severe increases in the concentration 
o f  homocysteine refer to levels o f  16-30, 31-100 and more than 100 pM  respectively. 
Only a small fraction (<2%) o f  plasma total homocysteine circulates in the thiol form. 
The remainder is a mixture o f  disulfide derivatives, including homocystine, 
homocysteine-cysteine mixed disulfide, and protein bound disulfides (Mudd et al, 
2000).
Moderate increases in homocysteine levels may result from a combination o f  genetic 
and dietary factors. High homocysteine levels can occur as a result o f  dietary vitamin 
deficiency without the genetic defects that cause homocystinuria (M iller et al, 1994). 
Dietary deficiencies in vitamin B 12  and folic acid produce milder increases in plasma 
homocysteine concentration than found in homocystinuria, and dietary intake and 
plasma levels o f  these vitamins are inversely related to levels o f  plasma homocysteine 
(Rimm et al, 1998). Homocysteine levels begin to rise at plasma levels o f  folate, 
vitamin B 12  and vitamin B6 that are regarded as within the low normal range (Selhub et 
al, 1993). Folic acid and vitamin B 12  protect against the build-up o f  homocysteine in 
the blood by conversion to methionine. Vitamin B6 also prevents the accumulation o f
2 0
homocysteine by converting it to cysteine and other compounds excreted in urine. 
Supplementation o f  diet with vitamins is now seen as an effective therapy for 
hyperhomocysteinaemia.
1.3.2 In vitro research
In vitro experimental research suggests that an increase in homocysteine concentration 
may cause atherosclerosis by a combination o f  endothelial injury (W oo et al, 1997) 
smooth muscle proliferation (Tsai et al, 1994; Tang et al, 1998), platelet activation and 
thrombogenesis (Den Heijer et al, 1996; Rodgers and Kane, 1986; Rodgers and Conn, 
1990). Oxidative metabolism o f  homocysteine may play a role in endothelial 
dysfunction (Loscalzo, J., 1996). Oxidation o f  homocysteine stimulates the production 
o f  reactive oxygen species, such as super oxide anion, hydrogen peroxide and hydroxyl 
radical, all o f  which create a potent oxidative stress (Andersson, 1995; Misra, 1974).
Homocysteine interacts with nitric oxide to produce S-nitrosohomocysteine at 
physiological concentrations, which amplifies the vasoprotective effects o f  nitric oxide. 
Normal endothelial cells detoxify homocysteine by releasing nitric oxide, which in turn 
leads to the formation o f  S-nitrosohomocysteine (Stamler et al, 1993). This reaction 
decreases the production o f hydrogen peroxide following oxidation o f  sulphydryl 
groups and represents a protective mechanism against the adverse effects o f  
homocysteine. Although prolonged exposure and high homocysteine concentrations 
result in impaired nitric oxide production. Therefore chronically elevated homocysteine 
concentrations appear to cause a self-perpetuating cycle that eventually overwhelms the 
capacity o f  the endothelial cells to reduce the toxicity o f  homocysteine (Stamler et al,
1993).
These in vitro studies imply that homocysteine at high concentration may cause many 
o f  the pathological processes associated with atherosclerosis. The problem with many o f  
these studies however is that the homocysteine concentrations used were in the 
pharmacological range (up to 1 mM) and not relevant to the levels present 
physiologically. The suggested effects proposed by the studies must, therefore, be 
interpreted with caution.
21
It is w ell know that endothelial damage has an adverse effect on flow  mediated 
dilatation o f  large arteries, an endothelium dependent mechanism which is believed to 
be an early indicator o f  the atherosclerotic process. In a study by W oo et al, (1997) 
impairment o f  brachial artery endothelium-dependent dilatation in patients with raised 
homocysteine levels (mean(s.d.) 34.8(8.5) (j,M) was demonstrated. Although there were 
only 14 participants in the study, endothelial dysfunction was demonstrated in vivo at 
clinically relevant concentrations.
Vascular smooth muscle cell proliferation with subsequent formation o f  extra cellular 
matrix collagen is an important feature o f  atherosclerosis (Ross, 1999). Homocysteine 
has been shown to increase D N A  synthesis with subsequent smooth muscle 
proliferation (Tsai et al, 1994; Tang et al, 1998) in a dose-dependent manner at plasma 
concentrations ranging from 25 to 500 jxM.
The vascular endothelium maintains a non-thrombogenic surface through the 
antithrombin III and thrombomodulin-protein C anticoagulant pathways (Williams,
2001). Treatment o f  endothelial cells with homocysteine induces enhanced factor V  
activity (a procoagulant factor) (Rodgers and Kane, 1986) and reduced production o f 
protein C  (Rodgers and Conn, 1990). The concentrations used (up to 1 mM) were again 
very high compared to pathophysiological levels, although a study has shown that 
moderate increases in plasma homocysteine level is a risk factor for deep vein 
thrombosis (Den Heijer et al, 1996).
Leukocyte adhesion to the endothelium is an important part o f  the process o f 
atherogenesis (Ross, 1999). The build up o f  leucocytes in inflamed tissues is caused by 
adhesive interactions with endothelial cells in the microcirculation (Granger and Kubes,
1994). A  study by Pruefer et al, (1999) has shown increased adhesion and trans- 
endothelial migration o f  leucocytes when the mesentery o f  rats was perfused with 
plasma concentrations o f  homocysteine ranging from 1 to 5 |J.M. Immunohistochemical 
staining demonstrated significantly increased P-selectin and intercellular adhesion 
molecule I (IC A M ) expression on the intestinal venules after homocysteine perfusion. 
These results were not supported by w ork from Dudman and Hale, (1997) who found
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no increase in IC A M -1 expression on the endothelium following treatment with 
homocysteine. The possibility that homocysteine affects adhesion indirectly by 
activating leucocytes, which then interact with and cause pathological changes in the 
vascular endothelium, w as then investigated. Endothelial-leukocyte interaction was seen 
to be mediated by the neutrophil-docking protein com plex C D llb -C D 18  (Dudman et 
al, 1999). Despite the impressive list o f  atherosclerotic effects o f  homocysteine, its 
biological relevance remains questionable. The effects described above occur only at 
concentrations o f  homocysteine in the pharmacological range. It is uncertain how lower 
concentrations might be associated with an increased risk o f  atherosclerotic disease.
1.3.3 In vivo research
Even though there is a lot o f  in vitro research to support a link between raised 
homocysteine concentration and atherosclerosis, clinical studies have produced mixed 
results. A  number o f  prospective studies analysing the link between homocysteine and 
cardiovascular disease have been published (Nygard et al, 1997; Bostom et al, 1997; 
Wald et al, 1998). V erhoef et al, (1997) observed almost no association between plasma 
homocysteine level and risk o f  angina pectoris with subsequent coronary artery bypass 
surgery. In a study carried out by Folsom et al, (1998) it was found that fasting total 
homocysteine concentration was correlated positively and strongly at high levels with 
the age-, race- and centre-adjusted incidence o f  coronary heart disease in women, but 
not in men. Adjustment for other risk factors, however, abolished this association. This 
suggests that total homocysteine concentration was not independently associated with 
coronary heart disease. The Physicians' Health Study, after a 5-year follow-up, showed 
that plasma homocysteine levels above the 95th percentile o f  the control distribution 
were associated with a 3.4-fold increased risk o f  myocardial infarction, however, after 
the 7.5 year follow  up, the relative risk was only 1.7 and this was no longer statistically 
significant (Stampfer et al, 1992). This lack o f  association may be explained by a 
variation in homocysteine levels within subjects over time, which may have attenuated 
the effect. This result, however, questions the role o f  homocysteine in atherosclerotic 
disease.
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Associations are described between plasma homocysteine concentration and carotid 
artery intimal-medial w all thickening (M alinow et al, 1993) and the prevalence o f  
carotid artery stenosis (Selhub et al, 1995). V erhoef et al, (1994) in a sample o f  patients 
taken from the Physicians' Health Study, studied 109 patients who developed an 
ischaemic stroke over a 5-year period. They found no association between increased 
plasma homocysteine level and the risk o f  ischaemic stroke. A  prospective study carried 
out in Finland examined the association between homocysteine and atherosclerotic 
disease in middle-aged men and women, the results showed no association with 
myocardial infarction or stroke (Alfthan et al, 1994).
Conflicting evidence was reported in a retrospective study (Perry et al, 1995), which 
showed a strong independent association between homocysteine level and stroke in a 
sample o f  middle-aged British men. This was consistent with the theory that raised 
homocysteine concentration caused stroke. In a study carried out by Taylor et al, (1999) 
it was reported that an increase o f  1 |J.M in plasma homocysteine concentration was 
associated with a 5.6 per cent increased likelihood o f  death from vascular disease. After 
they carried out a retrospective study, although a similar age o f  onset o f  symptoms was 
noted in patients with raised and normal homocysteine levels, a significant progression 
in lower-limb occlusive disease and coronary artery disease was found in those with 
raised homocysteine levels. N o such association was noted for cerebrovascular disease 
(Taylor et al, 1991). They followed this work with a prospective study o f  351 patients 
with symptomatic peripheral arterial disease. N o statistically significant relationship 
between decreasing ankle: brachial pressure index and increasing carotid stenosis was 
found in patients with increased homocysteine levels (Taylor et al, 1999).
Although some o f  the studies published do conflict, the consensus is that there is an 
undeniable link between raised homocysteine and cardiovascular disease (Eikelboom et 
al, 1999).
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1.4 Objectives of this study
The objective o f  this study was to investigate whether both C L A  and/or homocysteine 
modulate the expression and/or activity o f  two distinct vascular endothelial cell (EC) 
components; Nitric oxide synthase (eN OS) and Cox. Both eN OS and C ox, responsible 
for production o f  nitric oxide and prostacyclin respectively, have been strongly 
implicated in the endothelial maintenance o f  vascular hemodynamic mechanisms.
The experiments were designed to examine the effects o f  chronic treatments (up to 24) 
on the expression o f  eN OS and Cox 1 protein and steady state RNA. Nitrite and PGF|a 
levels in the conditioned were assayed as an index o f  eN OS and C ox I activity, after 
acute (up to 180 min) and chronic (up to 72 hours) treatment.
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2 .1  M a te r ia ls
Chapter 2 M aterials and M ethods
A G B  Scientific (Dublin, Ireland)
Whatmann Chromatography paper
A lexis Biochem icals (Nottingham, U K ) 
2,3-diaminonapthalene
Amersham Pharmacia Biotech (Buckinghamshire, U K) 
Anti-mouse 2° antibody, HRP conjugated 
Anti-rabbit 2° antibody, HRP conjugated 
E C L  Hybond nitrocellulose membrane 
E C L  Hyperfilm
Rainbow molecular w eight marker, broad range (6-175kDa)
Assay Designs (Michigan, USA)
EIA kit for 6-keto-Prostaglandin F !a
BioRad (Alpha Technologies, Dublin)
Bio-Dot SF Micro filtration apparatus
B io  Sciences Ltd (Dun Laoghaire, Ireland)
D M E M
d N TP ’ s
DEPC-treated water 
Trizol® reagent
Caym an Chem ical Com pany (M ichigan, U SA )
C o x  I monoclonal antibody 
eN OS polyclonal antibody 
C orn ell C ell Repository (NJ, U SA )
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Bovine Aortic Endothelial Cells (BAECs)
MWG (Cork, Ireland)
Cox I primer set 
Cox H primer set 
eNOS primer set 
(3-actin primer set 
GAPDH primer set
Nu-Chek-Prep Incorporated (Elysian, MN)
A  preparation o f  mixed C L A  was used in this study. The isomer composition was as 
follow s; t9/cl 1-C LA  + c9 / tll-C L A  (41% ), clO /tl2-C L A  (44%), tlO /tl2-CLA (10%), 
t9/tl 1-C L A  + c9/cl 1-C L A  + cI0 /cl2 -C L A  (5%).
Single isomers o f  C L A  29.5%  c 9 /1 11 (18:2) and 29%  tlO/c 12 (18:2) were also 
obtained.
PALL Corporation (Dun Laoghaire, Ireland)
Biotrace nitrocellulose membrane
Pierce Chem icals (Cheshire, UK)
B C A  protein assay kit
Supersignal West Pico chemilumescent substrate
Promega (UK)
Taq DNA Polymerase 
MLV-RT 
RNase H 
Oligo dT
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Sarstedt (Drinagh, W exford, Ireland)
T25 tissue culture flasks 
T75 tissue culture flasks 
T 175  tissue culture flasks
6-well tissue culture plates
5,10 and 25ml serological pipettes
15 and 50ml falcone tubes
Sigm a Chem ical Com pany (Poole, Dorset, England)
ß -glycerophosphate 
2-mercaptoethanol 
A cetic A cid  
Acetone 
Agarose
Ammonium Persulphate 
Bisacrylam ide 
Bovine Serum Albumin 
Brightline Haemocytometer 
Bromophenol blue 
Chloroform
Calcium  Ionophore A 2 3 187
DL-Hom ocysteine
E D T A
E G T A
Ethidium Bromide 
Fetal C a lf  Serum 
G lycerol 
G lycine
Hanks Balanced Salt Solution 
Hydrochloric acid 
Isopropanol 
Leupeptin
Methanol
Mineral oil (molecular grade) 
Penicillin-Streptomycin (lOOx) 
Ponceau S 
Potassium Chloride 
Potassium Iodide 
Potassium Phosphate (Dibasic) 
RPM I-1640 
SDS
Sodium Chloride 
Sodium Hydroxide 
Sodium Nitrite 
Sodium Orthovanadate 
Sodium Phosphate 
Sodium Pyrophosphate 
TEM ED 
Tris Acetate 
Tris Base 
Tris Cl 
Triton X-100
Trypsin-EDTA solution (lOx) 
Tween 20
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2.2 Methods
2.2.1 Preparation and Storage of CLA stocks
A  synthetic source o f  C L A  isomers obtained from Nu-chek Inc. was used in this study. 
The mixture contained primarily 29.5%  9c, 1 l t ( l 8:2) and 29%  lOt, 12c (18:2) C L A  
isomers but also contained trace amounts o f  other isomers. Individual purified solutions 
o f  29.5%  9c, 1 l t ( l 8:2) and 29% lOt, 12c (18:2) C L A  isomers were also used. Stock 
solutions o f  100 mg/ml were made up in 95%  ethanol (EtOH) and were stored at -20°C. 
W orking stock dilutions were made up at concentrations o f  10,000 and 2000 pg/ml and 
also stored at -20°C. Dilutions were made in RPMI 1640 tissue culture media to give 
treatment concentrations o f  0-15 (xg/ml (0-53 pM).
2.2.2 Cell culture Techniques
A ll cell culture w as carried out in a sterile environment using a Bioair instruments aura 
2000 M A C  laminar airflow cabinet. C ells were visualized with an Olympus CK30 
phase contrast microscope.
2.2.2.1 Culture of Bovine Aortic Endothelial Cells (BAEC)
The B A E C  cell line (Corriell Cell Repository-NJ, U SA ) used in the study was 
maintained in RPM I 1640 supplemented with 10% fetal c a lf  serum (FCS) and 
antibiotics (50 U/ml penicillin, 50 pg/ml streptomycin). Cells were cultured in 25cm2 or 
75cm 2 tissue culture flasks or 6 w ell plates. Only cells between passage 8 and 15 were 
used for experiments. Trypsination was carried out remove cells from the flask for 
passing. For trypsination, the media was removed and cells were washed in Hanks 
Balanced Salt Solution (H BSS) twice. For 25 cm2 flask 1ml o f  IX  trypsin 
ethylenediamine tetracetic acid (ED TA ) (10%  v/v trypsin E D T A  was made up with 
H BSS) was added to the flask. The flask was then incubated at 37°C for 5 minutes or 
until all the cells had detached from the surface. 10ml o f  growth medium was then 
added to the flask to inactivate the trypsin. The cell suspension was then removed from 
the flask and spun down in a centrifuge at 5000 xg  for 5 minutes. The supernatant was 
then removed and cells resuspended in fresh growth medium. For routine passing o f 
cells dilutions o f  1:3 to 1 :8 were made depending on when confluent cells were needed
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again. Typically, 2 ml o f  the 10 ml cell suspension (1:5 dilution) was mixed with 13 ml 
o f  fresh growth medium and poured into a 75 cm2 tissue culture flask. The cell line was 
incubated in a humid, 5%  v/v C 0 2 atmosphere at 37°C using a Hera water jacketed cell 
culture incubator.
2.2.2.1 Cell counts
C ell counts were carried out using a Sigm a brightline haemocytometer. For experiments 
cells were seeded into 6 w ell plates and 25 cm tissue culture flasks at densities o f 
10,000 to 50,000 cells per cm2, depending on when confluent cells were needed. 
Briefly, a drop o f  the cell suspension was used to fill the counting chamber o f  the 
haemocytometer. The number o f  cells in each o f the four quadrants was counted and 
averaged, the number o f  cells in the suspension was then calculated as follows,
The number of cells per millilitre = Number of cells counted per quadrant X dilution (if used) X 10,000
2.2.2.3 Storage of BAEC in liquid nitrogen
For long term storage the B A E C  were maintained in liquid nitrogen in a cryofreezer 
unit. Cells to be stored were trypsinised and centrifuged as described in section 2.2.2.1. 
The pellet o f  cells was then resuspended in 1ml o f  freezing media (10%  FCS, 1%  
D M SO ) and then transferred to a sterile cryotube. The cell suspension was then 
graduately frozen in a Nalgene cryo freezing container, which was placed in a -80°C 
Freezer, at a rate o f  -l°C /m in. After one night in the -80°C the cryovials were then 
transferred to the Thermoylen locator jr. cryostorage system. Cells were recovered from 
liquid nitrogen by thawing rapidly at 37C and then transferred to a sterile falcone tube 
containing 10 ml o f  fresh growth media. The cells were then spun down in a centrifuge
at 5000 xg  for 5 minutes. The supernatant was then removed and the cells resuspended
— 2 in 15 ml o f  fresh growth media. The cell suspension was then transferred to a 75 cm
tissue culture flask and incubated in the Hera C O 2 incubator. These cells were then
passed twice, to ensure complete recovery, before they were used in an experiment.
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2.2.3 Preparation of whole cell lysates
Growth media was removed and cells were washed in H BSS twice. The cells were then 
harvested using a cell scraper into 5ml o f  H BSS. The cell suspension was then spun 
down in a centrifuge at 5000 xg for 5 minutes. The supernatant was removed and the 
cells were resuspended in 50-100 p.1 o f  IX  lysis buffer (20 mM Tris, 150 mM  NaCl, 1 
m M N a 2E D T A , 1 m M  E G T A , 1%  Triton X-100, 2.5 m M  sodium pyrophosphate, 1 mM 
B-glycerophosphate, 1 mM  sodium orthovanadate, 1 |ig/ml Leupeptin). The lysates 
were then frozen and thawed three times and then subjected to ultrasonication using a 
sonic dismembrator. Samples were then stored at -80°C prior to use for western blot 
analysis.
2.2.4 Bicinchoninic acid (BCA) protein microassay
_l_2 4-1 « « ,
This method combines the reduction o f  Cu to Cu by protein in an alkaline medium 
(the biuret reaction) with the selective colorimetric detection o f  the cuprous cation using 
a reagent containing bicinchoninic acid. This water-soluble complex exhibits a strong 
absorbance at 562 nm that is linear with increasing protein concentrations over a broad 
w orking range o f  20-2,000 (ig/m I. The two separate reagents used were supplied in the 
commercially available assay kit (Pierce Chemicals): A , an alkaline bicarbonate 
solution and B, a copper sulphate solution. A  working solution was prepared by mixing
1 part reagent B  with 50 parts reagent A . On a microtitre plate 200 |J.l o f  the working 
solution was added to 2ja.l o f  the whole cell lysate or Bovine serum albumin (BSA) 
protein standard. The plate w as then incubated at 37°C for 30 min. The absorbance o f  
each w ell was then read at 560 nm using a micro plate reader. A ll samples and 
standards were tested in triplicate. Quantitation was carried out by interpolation from a 
B S A  standard curve ( 0 - 1 0  ja.g/fxl).
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2.2.5 Preparation of total RNA from BAEC
Total R N A  was isolated from B A E C  using Trizol® reagent according to the method o f 
Chom czynski and Sacchi (1987). The reagent, a mono-phasic solution o f  phenol and 
guanidine isothiocyanate, is a modification on the isolation method developed by 
Chomcznski and Sacchi. Trizol reagent maintains the integrity o f  R N A  while disrupting 
cells and dissolving cell components. Growth media was removed and cells were 
washed with H BSS twice. Cells were then lysed directly by adding trizol reagent to the 
flask, 1 ml per 10 cm2. The lysate was transferred to a falcone tube and incubated for 5 
minutes at 15°C to 30°C to permit the complete dissociation o f  nucleoprotein 
complexes. 0.2 ml o f  chloroform per 1 ml o f  trizol was then added, the tube was then 
shaken vigorously for 15 seconds and then spun down at 12,000 xg  for 15 min at 2°C to 
8°C. The resulting aqueous phase was then transferred to a fresh tube. R N A  was then 
precipitated by m ixing with isopropyl alcohol, 0.5 ml per 1 ml o f  trizol. The samples 
were then incubated at 15°C to 30 °C for 10 min and spun down at 12,000 xg  for 10 min 
at 2 to 8 °C. The R N A  was then visible as a gel like pellet on the side and bottom o f  the 
tube. The supernatant w as then removed and the pellet washed with at least 1ml o f  75%  
ethanol per 1 ml o f  trizol used. The sample was then mixed by vortexing and spun down 
at 7,500 xg  for 5 minutes at 2 to 8°C. The supernatant was removed and the pellet 
washed again in ethanol. After washing the pellet was air dried and the R N A 
resuspended in 30-50pl o f  RNase free water. A ll total R N A  preparations were stored at 
-80 °C.
2.2.6 Quantitation of total RNA in samples
Quantitation o f  total R N A  in samples was carried out by absorption spectroscopy. The 
absorption o f  the sample was measured at several different wavelengths to assess purity 
and concentration. Briefly, 2 |il o f  the sample was added to 1000 jxl o f  Tris E D TA (TE) 
buffer (10 mM TrisCl, 1 mM ED TA , made up in RNase free water pH 7.4). The 
absorbance was then read using matched quartz quvettes, and using TE buffer as a 
blank. B y  measuring absorbance at 280 nm and 260 nm, purity was estimated using the 
A 260/A280 ratio. A  ratio o f  1.9 to 2.0 was indicative o f  a highly purified preparation o f  
R N A . A  ratio lower than this was indicative o f  protein contamination. Absorbance at 
230 nm reflected contamination o f  the sample by phenol, while absorbance at 325 nm
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suggests contamination by particulates or a dirty cuvette. The concentration of RNA in 
the sample was determined using the A260 reading as follows:
Concentration of single stranded RNA |xg/ml = A260 x Dilution factor x 40 
All samples were tested in triplicate and were kept on ice at all time during the 
experiment.
2.2.7 Design of PCR primer sets 
A web based program called multialin was used to design the primer sets used in this 
study "Multiple sequence alignment with hierarchical clustering" (Corpet, 1988). This 
program allows alignment of sequences from a number of different species so primers 
can be designed from highly conserved areas. Primers were designed with ~50% GC 
content so the annealing temperature for all sets was ~55°C.
Cox I primer set, from bovine sequence fragment size: 650 base
pairs
Forward primer 5’ - A AT TCC AGT ACC GCA ACC - 3’
Reverse primer 5’ - AGG TCT TGG TGT TGA GGC A - 3’
Cox II primer set, designed by consensus (rat, mouse and human sequences) 
fragment size: 280 base pairs
Forward primer 5’ - TTT GAA GAA CTT AC A GGA G - 3’
Reverse primer 5’ - TAT TGC AGA TGA GAG ACT GA - 3’
eNOS primer set, designed from bovine sequence fragment size: 300 base
pairs
Forward primer 5’ - GCT TGA GAC CCT CAG TCA GG - 3’
Reverse primer 5’ - GGT CTC CAG TCT TGA GCT GG - 3’
P-actin primer set, designed from mouse sequence fragment size: 550 base
pairs
Forward primer 5’ - ATC CTG CGT CTG GAC CTG GCT - 3’
Reverse primer 5’ - CTT GCT GAT CCA CAT CTG GTG - 3’
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GAPDH primer set, designed from bovine sequence fragment size: 341 base
pairs
Forward primer 5’ - TCC TGC ACC ACC A AC TGC TT - 3’
Reverse primer 5’ - TGC TTC ACC ACC TTC TTG AT - 3’
2.2.8 Dot blot imunoasay
A dot blot apparatus was used to immobilize protein from whole cells lysates onto 
nitrocellulose membranes. The technique was used to optimise primary antibody 
concentrations for western blot analysis. A Bio-Dot SF Micro filtration apparatus (170- 
6542) from Bio-Rad was used for all dot blots. The dot blot procedure was carried out 
as follows: The Bio-Dot SF apparatus and gasket was cleaned and dried prior to
assembly. The apparatus was assembled as described in the manufactures instruction
manual. Three sheets of Whatmann chromatography paper were wetted in PBS. 
Nitrocellulose membrane was pre-wetted in distilled water and then wetted in PBS. The 
filter paper and membrane were then placed into the apparatus as described in the 
instruction manual. The four screws were then tightened in a diagonal crossing pattern 
and under vacuum to ensure there is no cross-well contamination. The membrane was 
rehydrated with 100 |al PBS per well. The flow valve was then adjusted so that the 
vacuum chamber was open to the atmosphere. Each well was filled with 200 pi of 
protein solution (BAEC whole cell lysate) to give a final amount of protein of 10 pg. 
The samples are then allowed to filter through the membrane by gentle vacuum. Each 
sample well was then washed with at least 200 pi of PBS. The wash liquid was then 
pulled through by applying gentle vacuum. After the wells were completely drained, the 
membrane was removed from the apparatus. The membrane was then blocked and 
incubated in primary and secondary as described in section 2.2.9.4. there was one 
variation, the dilutions of primary antibodies were numerous. The sample wells were 
cut into seven sections and incubated with seven different sections of primary antibody. 
Development and detection of the blot was carried out as described in section 2.2.9.5.
34
2.2.9 SDS PAGE and Western blot analysis
2.2.9.1 Sample preparation
An aliquot of the sample, giving a concentration of 25 pg protein, to be analysed was 
mixed 1:4 v/v with 4x Sample Solubilisation Buffer (SSB) (4 g Sodium dodecyl sulfate, 
20 ml glycerol, 2 ml P mercaptoethanol, 0.04 g Bromophenol blue, 24 ml 0.25 M 
TrisCL, made up to 50 ml, pH to 6.8) and made up to 50 pi with lysis buffer in a sealed 
screw-cap micro centrifuge tube. The sample was then heated to 100°C for 5 minutes. 
The sample was then placed on ice until ready to load onto gel. Prepared in this way 
there was enough volume to load two wells, 20 pi, or 10 pg, per well.
2.2.9.2 Preparation and runing of gel
An Atto AE-6450 Dual Mini Slab Kit was used for all protein electrophoresis carried 
out during the study. Before running the gel, the apparatus needed to be set up and 
reagents made up. This was carried out as follows. All gel cast parts were cleaned with 
ethanol prior to use. The gel cast was prepared as described in the manufacturers 
operating instructions. Stock solutions of 4% (stacking), 7% (resolving) and 12% 
(resolving) unpolymerised Bis Acrylamide were made up and stored at 2-8°C. As an 
example, 250 ml of the 4% stacking gel solution was made up as follows:
10% w/v Sodium dodecyl sulphate - 2.5 ml
Stacking gel buffer (0.5M Tris/HCL, pH 6.8) - 62.5 ml
Acrylamide/ Bis Acrylamide (40% Soln. 29:1 Ratio) - 24.375 ml
Ultra pure water - 160.625 ml
An aliquot of the resolving gel stock solution (10 ml per gel) was mixed with 50 pi of 
freshly prepared 10% Ammonium persulphate and 15 pi of TEMED, this was then 
poured into the gel cast. A few drops of water saturated butanol was then added to 
remove any bubbles, the gel was then allowed to polymerise for 10-20 minutes. When 
set the unpolymerised liquid was poured off. The stacking gel was prepared in the same 
manner. This was then poured onto the resolving gel, the 12-well comb was then put in 
place and again the gel was allowed to polymerise for 5-10 minutes. The chamber was 
then half filled with reservoir buffer (25 mM Tris, 192 mM Glycine, 0.1% Sodium
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dodecyl sulphate). When the gel set, the comb, clips and casket was removed and the 
gel cast was clipped into the electrophoresis chamber. The chamber was then filled with 
reservoir buffer and the lanes flushed out to remove unpolymerised Bis Acrylamide. 
The lanes were then loaded with samples. The gel was then run at 200 V, 90 mA and 
150 W until the dye front had migrated to the end of the gel.
2.2.9.3 Semi-dry electrobloting
An Atto AE-6675 semi-dry blotting apparatus was used for all electroblotting during 
this study. When the gel had finished running, it was removed from the cast and the 
stacking gel was removed from the resolving gel. The resolving gel was then soaked in 
semi-dry transfer buffer (25 mM Tris, 192 mM glycine, 20% methanol) for 5 minutes. 
Two stacks of 10 sheets of Whatmann chromatography paper was cut to exactly the 
same size of the resolving gel (9x 6 cm2). The chromatography paper was also soaked in 
semi-dry transfer buffer. A sheet of PALL BioTrace nitrocellulose membrane was cut 
to the same size of the resolving gel (9x 6 cm2) and pre-soaked in ultra pure water, then 
soaked in semi-dry transfer buffer. The transfer stack was set up as follows: 10 sheets of 
Whatmann chromatography paper, the nitrocellulose membrane, the resolving gel and 
finally 10 sheets of Whatmann chromatography paper. A pen was rolled over the stack 
to remove any air bubbles. The apparatus was then closed and run at 100 V, 600 mA, 
150 W for 45 minutes.
2.2.9.4 Ponceau S staining, blocking and antibody incubations
When the transfer was finished the nitrocellulose membrane was removed and stained 
in Ponceau S for 5 minutes. The membrane was then rinsed briefly in ultra pure water to 
remove any background staining. The membrane was placed between 2 acetates and an 
image was taken with an Epson perfection 1200S scanner. The image was saved and 
used to asses equality of protein loading across the gel. Then membrane was then 
destained in Phosphate buffered saline-Tween 20 (PBS-T20) (10 mM Tris, 100 mM 
NaCl, 0.1% Tween 20) until all Ponceau S stain was removed.
The membrane was then blocked in a 5% Bovine serum albumin solution (BSA) (5g of 
BSA in 100 ml of PBS-T20) for 2 hours at room temperature on an orbital shaker. The
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membrane was then washed for 2x2 minutes in PBS-T20. The primary antibody was 
diluted in a 2.5% BSA solution. The dilution factor for each antibody was determined 
empirically. The membrane was incubated in primary antibody for 3-4 hours at room 
temperature on an orbital shaker.
The membrane was then washed 3 x 1 0  minutes in PBS-T20. The secondary antibody 
was diluted in a 2.5% BSA solution. The membrane was incubated in secondary 
antibody (conjugated to horse radish peroxidase) for 3 - 4 hours at room temperature on 
an orbital shaker. The membrane was then washed 3x10 times in PBS - T20. Excess 
wash buffer was drained from the membrane by holding gently in a forceps and 
touching the edge against a tissue.
2.2.9.5 Detection and development of blot
Supersignal west pico chemilumescent substrate from Pierce was the detection reagent 
used to develop western blots carried out in this study. This detection system employs a 
mix consisting of equal volumes of enhancer solution and stable peroxide solution. This 
solution is a highly sensitive enhanced chemiluminescent substrate for the development 
of utilising a horseradish peroxidase (HRP) label.
The detection reagents were removed from storage at 2-8°C and allowed to equilibrate 
to room temperature before opening. An equal volume of reagent A was mixed with 
reagent B, usually a total of 1 ml for one membrane. The membrane was placed, protein 
side up, on an acetate and the detection reagent place on top ensuring the whole 
membrane was covered. A second acetate was then placed on top. The membrane was 
incubated for 10 minutes at room temperature. The excess detection reagent was then 
drained off by holding gently in a forceps and touching the edge against a tissue. The 
blot was placed down on to a fresh piece of cling film and wrapped up, any air bubbles 
were gently removed.
In the dark room, the wrapped blot was placed, protein side up in an x-ray film cassette. 
A sheet of Amersham Hyperfilm ECL auto radiography film was placed on top of the 
membrane, the cassette was closed and the film was exposed for between 10 seconds
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and 5 minutes depending on the antibody. The film was then removed and developed in 
an Amersham hyperprocessor automatic developer.
2.2.10 Reverse Transcriptase Polymerase Chain Reaction (RT-PCR)
2.2.10.1 Reverse transcriptase
All total RNA samples were prepared by the Trizol® method as previously described in 
section 2.2.5. RNA preparations were then quantified by absorbance spectroscopy as 
described in section 2.2.6. Reverse transcriptase was carried out using Promega Murine 
Leukemia Virus Reverse Transcripase (MLV RT) as follows. The initial amount of 
RNA used for each primer set was determined empirically to ensure a semi quantitative 
analysis section . The initial amount of RNA used for each primer set can be seen in 
Table 2.2.10.2. For the purpose of this protocol 2 pg of RNA was transferred to an 
RNase free microcentrifuge tube. To this 0.5 jig of Promega Oligo dT primer was 
added. This ratio of amount of RNA to Oligo dT remained constant for each primer set 
used. The volume was then made up 15 pi with RNase free water. The tube was heated 
to 70°C for 5 minutes to melt secondary structure within the template. The tube was 
cooled immediately to prevent secondary structure from reforming. The following 
components were added to the annealed primer/template in the order shown:
MLV 5x Reaction buffer 5 pi
dATP, lOmM 1.25 pi
dCTP, lOmM 1.25 pi
dGTP, lOmM 1.25 pi
dTTP, lOmM 1.25 pi
MLV-RT 200 units
Make up to a total of 25 pi with RNase free water
The components were mixed by gently flicking the tube. The mix was then spun down 
in a microfuge and incubated for 60 minutes at 42°C. 1 pi of RNase H (2 units/ pi). The 
mix was then incubated for 20 minutes at 37°C. A negative control was also carried out 
with every RT reaction. The control contained no reverse transcriptase, any
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amplification by RT PCR from the negative control was indicative of genomic DNA 
contamination. All RT samples were stored at -80°C until needed for PCR.
2.2.10.2 Polymerase Chain Reaction (PCR)
All PCR was carried out using Promega Taq DNA Polymerase. A PCR mix was made 
up for each sample to be amplified. The mix was made up as follows:
RNase free water 36.5 (il
Buffer lOx 5 pi
dNTP lOmM 1 pi
MgCl2 25mM 3 pi
Forward primer lOpM 1 pi
Reverse primer lOpM 1 pi
Taq Polymerase 2-5u/pl 0.5 pi
RT sample 2 pi
Mineral oil 50 pi
When the reaction mixture was made up it was placed in the PCR thermocycler. All 
PCR was carried out in a Hybaid PCR thermocycler (SPRT 001). The program used 
was optimised for each primer set and is summarized in Table 2.2.10. For the purpose 
of this protocol the program was as follows:
94°C -  3 minutes 
94°C -  1 minute 
55°C -  2 minutes 
72°C -  3 minutes 
4°C -  Hold
30 cycles
When finished the samples were stored at -80°C until needed for agarose gel 
electrophoresis.
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Table 2.2.10.2: A summary of the empirically determined conditions employed
for each primer set used in RT-PCR.
Cox I Cox II eNos GAPDH (3-actin
Initial RNA 
concentration
1 Hg 1 0.2 ng 0.5 Hg 0.2 |ig
Volume of 
MgCl2 
(25 mM)
3 nl 3 (J.1 3 nl 3 |xl 3 (J.1
Number of 
PCR cycles
35 40 25 25 25
Annealing
temperature
55°C” 55°C" 55°C" 55°C*+ 55°C*’
* The Cox II primer set was used qualitatively, not quantitatively and so the initial 
amount of RNA used did not need to be determined.
**Primers were designed with -50% GC content so the annealing temperature for all 
sets was ~55°C.
2.2.10.3 Agarose gel electrophoresis
All DNA gel electrophoresis was carried out using a GibcoBRL Horizon 20.25 Gel 
electrophoresis Apparatus. Before use the gel box was cleaned with ethanol and the gel 
cast was set up as described in the manufacturers instruction manual. A 2.5% agarose 
gel stock was made up by dissolving 12.5 g of agarose in 500 ml of lxTris Acetate 
EDTA (TAE) (40 mM Tris-Acetate, 1 mM EDTA). The agarose was dissolved by 
heating in a microwave (700 mHz) at full power for 5 minutes. 100 ml of the liquid 
agarose was then transferred to a fresh glass beaker. To this 250 fol of 200 (ig/ml of 
Ethidium Bromide (EtBr) solution was added and mixed thoroughly to give a final 
concentration of 0.5 (ig/ml EtBr. The agarose was then poured into the cast, the comb 
put into place and the gel allowed to set. Once set the comb was removed and the 
apparatus filled with lx TAE buffer. The gel was now ready to load and run. The 
samples were prepared as follows: 13 fxl of PCR product + 5 jj.1 of 4x loading dye. 8 (0.1
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was loaded each well in duplicate. The gel was run at 80 V, 110 mA and 150 W until 
the dye front had migrated % length of the gel. When finished the gel was placed on an 
Ultra Violet Products UV transilluminator for visualization. A picture was taken using a 
Kodak DC290 digital camera for documentation. The gel was then disposed of in the 
appropriate ethidium bromide waste container.
2.2.1 Enzyme Imunoasay for 6-keto-ProstagIandin Fia
Assay designs correlate -  Enzyme Immunoassay Kit (EIA) kits were used for 
quantitation of 6-keto-Prostaglandin Fia in conditioned media during this study. The kit 
is a competitive immunoassay for determination of 6-keto-PGFia. Briefly, a polyclonal 
antibody is employed to capture 6-keto-PGFia in the samples and standards. 6-keto- 
PGFic conjugated to alkaline phosphatase is used to compete for any antibody that 
might be left over. The mix is incubated for a short period, the excess reagents are then 
washed away and a substrate for alkaline phosphatase is added. After a short incubation 
time the enzyme reaction is stopped and the yellow colour generated is read on a 
microplate reader at 405nm. The intensity of the bound yellow colour is inversely 
proportional to the concentration of 6-keto-Prostaglandin F]a in either standards or 
samples. For further explanation of the principles of immunoassays please see the books 
by Chard (1990) and Tijssen (1985).
Prostacyclin (PGI2) is involved in platelet aggregation, vasorelaxation, and reproductive 
functions (Ylikorkala and Makila, 1985). However, PGI2 has a half life of 60 minutes in 
plasma but only 2 to 3 minutes in buffer. The production of PGI2 is typically monitored 
by measurement of 6-keto-PGFia. 6-keto-PGFia is produced by the nonenzymatic 
hydration of PGI2, and has been shown to be stable (Ylikorkala and Makila, 1985).
The assay was carried out as follows:
All reagents were brought to room temperature for at least 30 minutes prior to carrying 
out the assay. All samples and standards were run in triplicate.
1. 100 |il of standard diluent (growth media) was pipetted into the NSB and the Bo 
standard wells.
2. 100 (j.1 of standards #1 to #7 were pipetted into the appropriate wells.
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3. 50 pi of the samples were pipetted into the appropriate wells.
4. 50 pi of assay buffer was pipetted into the NSB wells.
5. 50 pi of blue conjugate was pipetted into each well, except the blank, TA and 
NSB wells.
Note: Every well was green in colour except the NSB wells which were blue.
The blank and TA wells were empty at this point and had no colour.
6. The plate was incubated at room temperature on a plate shaker for 2 hours at 
-500 rpm. The plate was covered with the plate sealer provided.
7. The contents of the wells were emptied and each well was washed out with 200 
pi of wash solution. This was repeated to give a total of 3 washes.
8. After the final wash the wells were emptied, and any remaining wash buffer was 
removed by firmly tapping on a lint free paper towel
9. 5 pi of the light blue conjugate (1:10 dilution) was added to the TA wells.
10. 200 pi of the p-Npp Substrate solution was added to every well. The plate was 
then incubated at room temperature for 45 minutes without shaking
11. 50 pi of stop solution was added to every well
12. The plate was then read immediately at an optical density of 405 nm.
The Results from the assay were calculated as follows:
1. The average Net Optical Density (OD) bound for each standard and sample was 
calculated by subtracting the average NSB OD from the average OB bound:
Average Net OD = Average Bound OD -  Average NSB OD
2. The binding of each pair of standard wells as a percentage of the maximum 
binding wells (Bo) was calculated using the following formula:
Percent Bound = NetOD x 100 
Net Bo OD
3 Using Microsoft Excel software a graph of Percentage Bound versus Logio 
Concentration of 6-keto-PGFia for the standards was plotted . A fourth order 
polynomial trend line was fitted to the plot and concentrations of 6-keto-PGF]a 
in the samples were determined by interpolation.
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2.2.12 Fluorometric Nitrite asay (DAN asay)
This rapid and sensitive fluorometric assay for quantification of nitrite is based upon the 
reaction of nitrite with 2,3-diaminonaphthalene (DAN) to form the fluorescent product, 
l-(H)-naphthotriazole. The assay can be used to detect 10 nM nitrite making it 50-100 
times more sensitive than the well know Griess assay. The assay is a modification of the 
method of Damiani and Burini (Misko et al, 1986). The assay was carried out as 
follows: 10 |il of freshly prepared DAN (0.05 mg/ml in 0.62 M HC1) is added to 100 jxl 
of the sample (conditioned media) or standard and mixed immediately. Standards are 
made up in the same media as the conditioned media. Sodium nitrite was used as the 
standard. After a 10 minute incubation at 20°C, the reaction is terminated with 5 |il of
2.8 N NaOH. The intensity of the fluorescent signal produced by the product is 
maximized by the addition of the base. Formation of the 2, 3-diaminonaphthotriazole 
was measured using a fluorescent plate reader with excitation at 365 nm and emission 
read at 450 nm.
2.2.13 Gel documentation system
Any results generated by Western blot and RT-PCR were photographed using a Kodak 
DC290 digital camera. The image generated was then analysed using Kodak ID 
(version 3.5.4) densitometry imaging software. Briefly, a mean densitometric value was 
determined for each band (Western blot or RT-PCR). The values generated for 
treatment bands were then corrected against values generated for control bands 
(GAPDH, P-actin for PR-PCR) and lanes (ponceau S for Western blot). The corrected 
values were then expressed as fold change relative to negative control. These results 
were finally represented as a graph in an Excel spreadsheet.
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2.2.14 Exposure of BAECs to cyclic stretch
The purpose of generating stretched samples was to use them as positive controls for the 
up regulation of eNOS and Cox I and II protein and RNA. BAECs were cultured in 
RPMI 1640 media supplemented with 10% fetal calf serum and antibiotics (50 U/ml 
penecillin, 50 mg/ml streptomycin). Cells were grown in a humidified atmosphere of 
5% C 02/95% air at 37°C. For all experiments, BAECs were seeded into 6-well 
Bioflex® plates (Dunn Labortechnik GmBH - Asbach, Germany) at a density of 
approximately 6x10s cells/well. Bioflex® plates contain a pronectin-coated silicon 
membrane bottom which enables precise deformation of cultured cells by 
microprocessor controlled vacuum (Banes et al, 1985). When cells had reached 
approximately 80% confluency, a Flexercell® Tension Plus™ FX-4000T™ system 
(Flexcell International Corp. - Hillsborough, NC) was subsequently employed to apply 
a physiological level of cyclic strain to each plate (0-5% strain, 60 cycles/min, 0-24 h). 
Following all experiments, media was collected and cells were washed twice in PBS 
before being harvested using a cell scraper. Sample were then prepared as described in 
section 2.2.3 for western blot and section 2.2.5 for RT-PCR. All samples were stored at 
-80°C.
2.2.15 Exposure of BAECs to pulsatile shear stres
The CELLMAX™ QUAD artificial capillary module (polypropylene cell-PPF70 from 
Spectrum Laboratories Inc.) was used to expose BAECs to pulsatile shear stress 
(Redmond, E.M. et al, 1995). The purpose of generating sheared samples was to use 
them as positive controls for the up regulation of eNOS and Cox I and II protein and 
RNA (Hendrickson et al, 1999).
The system consists of a bundle of 50 semi permeable fibronectin coated polyethylene 
tubes (outer diameter 630 (im, wall thickness 150 (j.m, luminal area 70 cm , outer 
surface area 100 cm2, extra capillary volume 1.4 ml, 95% MWCO 0.5 jim) encased in a 
plastic holding. Cell culture medium is pumped at the chosen flow rate from a reservoir 
bottle through the lumen of the capillaries via silicone tubing. To maintain constant pH, 
pC02 and p02, the QUAD system was housed in a standard humidified cell culture 
incubator. Gaseous exchange occurs across the silicone tubing.
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The module is equilibrated for 3 days, to remove any air bubbles, by circulating culture 
media throughout the tubing and capillaries. Following this, BAECs were harvested 
from conventional cell culture flasks using 0.125% trypsin-EDTA at 37°C and injected 
into the luminal area using a double syringe method. Briefly, cells are seeded (at 
densities of 10,000 to 50,000 cells per cm2) using a syringe in one luminal port and the 
displaced media is withdrawn using another syringe through the other port. Cells were 
allowed to adhere for 3 hours, after which the pump is set to low flow (0.3 ml/min; 6 
mm Hg; 0.5 dyn/cm2) for at least 3 days. For the physiologically relative high flow rate 
(25 ml/min; 56 mmHg; 23 dyn/cm2), the flow rate is increased steadily over ~5 hours 
until the desired flow rate is reached (t = 0). The cells were then harvested from their 
separate compartments after 24 hours. Briefly, the capillary bundle is first slowly 
flushed out with HBSS to remove any media containing FCS. BAECs are then 
incubated with ~5 ml of lx trypsin EDTA for 5min at 37°C. The cell suspension is then 
washed out with 20 ml of fresh culture media. The cells are then pelleted at 5000 xg and 
samples are prepared as described in section 2.2.3 for western blot and section 2.2.5 for 
RT-PCR.
2.2.16 Statistics
Results are expressed as mean ± sem. Comparisons between control versus treated cells 
were made by Student’s unpaired t-test, with statistical significance established at 
P<0.05.
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The purpose of this chapter is to present the experiments that were carried out to 
optimise the western immunoblot and RT-PCR methods employed during this study. 
When employing RT-PCR for semi-quantitative analysis, a titre for initial total RNA 
concentration must be made for each primer set used. The reason for this is to ensure 
that any resulting bands are amplified within a linear range, and so semi-quantitative 
comparisons can be made. Initial RNA concentration is the only condition changed 
between each sample during the titre experiment. MgCl2 concentration, annealing 
temperature and number of cycles remain constant. The optimised set of conditions for 
each primer set used in RT-PCR, as determined from these experiments, is summarised 
in Table 2.2.10.2.
For western immunoblot analysis, optimisation of the primary antibody concentration is 
required. The following experiments were carried out to empirically determine an 
optimal antibody concentration. A concentration of antibody needs to be used which 
would ensure maximum amount of binding to the target antigen, thus producing a 
maximal signal, with the lowest background binding. This is to ensure that any 
difference seen in target bands is not due to variation in antibody binding. The 
concentration of the secondary antibody and amount of protein loaded remain constant 
during the titre experiment.
Once optimised the conditions employed for western immunobloting and RT-PCR 
remained constant throughout the study.
Chapter 3 Optimisation of RT-PCR and Western blot protocols
3.1 Introduction
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3.2 Optimisation of primer sets for RT-PCR
3.2.1 Optimisation of the p-actin primer set
In order to ensure that equal amounts of total RNA are used in each RT-PCR reaction 
mix a housekeeping gene, whose expression was not regulated by the treatment, was 
also amplified from each sample. B-actin is a standard housekeeping gene and was used 
during this study. The (3-actin PCR product amplified between treatments must be equal 
before any observed change in eNOS or Cox I bands can be attributed to the treatment. 
If there was a difference it was compensated for by densitometric analysis.. The results 
from optimisation of the P-actin primer set are as follows:
Figure 3.2.1 Titre of initial BAEC total RNA concentration for the P-actin primer set 
used in RT-PCR
R N A  ng  
0.2 0.3
R N A  |ig
From this experiment it was determined that 0.2 (ig of total RNA produced 
amplification within a linear range for the P-actin primer set used under the set 
conditions of RT-PCR.
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3.2.2 Optimisation of the GAPDH primer set
A set of GAPDH primers were used as a housekeeping control for samples generated 
from shearing BAEC. These sheared samples were used as a positive control for the up 
regulation of Cox I. A titre for initial total RNA concentration was made for the 
GAPDH primer set used in RT-PCR. This is the only condition that changed between 
the samples. MgCb conc., annealing temperature and number of cycles remained 
constant, Table 2.2.10.2. The results from optimisation of the GAPDH primer set are as 
follows:
Figure 3.2.2: Titre of initial BAEC RNA concentration for the GAPDH primer set 
used in RT-PCR.
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From this experiment it was determined that 0.5 pg of total RNA produced 
amplification within a linear range for the GAPDH primer set used under the set 
conditions of RT-PCR.
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The results from optimisation of the eNOS primer set are as follows:
3.2.3 Optimisation o f  eNOS primer set
Figure 3.2.3 Titre of initial BAEC total RNA concentration for the eNOS primer set 
used in RT-PCR.
300 bp
DNA
Ladder 0.1
R N A  |ig
0.2 0.3 0.5
eNOS ~ 300pb
RNAng
From this experiment it was determined that 0.2 ju.g of total RNA produced 
amplification within a linear range for the eNOS primer set used under the set 
conditions of RT-PCR, Table 2.2.10.2.
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The results from optimisation of the Cox I primer set are as follows:
Figure 3.2.4: Titre of initial BAEC RNA concentration for the Cox I primer set used in 
RT-PCR.
3.2.4 Optimisation o f Cox I primer set
RNA (j,g 
0.7 1.0
Cox I -650
R N A  jig
From this experiment it was determined that 1 Hg of total RNA produced amplification 
within a linear range for the Cox I primer set used under the set conditions of RT-PCR, 
Table 2.2.10.2
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3.3 Optimisation o f primary antibody concentration for Western Blot
3.3.1 Optimisation of the eNOS primary antibody
The eNOS 1° antibody was optimised using the dot blot apparatus as described in 
section 2.2.8. Briefly, 10 jxg of BAEC whole cell lysate was immobilized on to 
nitrocellulose membrane a number of times. The blot was incubated with various 
concentrations of eNOS 1° antibody and subsequently with a 1:15,000 dilution of anti 
rabbit 2° antibody. The blot was then developed as described in section 2.2.9.5. The 
purpose for this experiment was to empirically determine the optimum dilution of eNOS 
1° antibody that will produce a maximal signal with 10 jag of BAEC whole cell lysate. 
The results were as follows:
Figure 3.3.1 Results from dot blot immunoassay with 10 (j.g of BAEC whole cell 
lysate. Various concentrations of eNOS 1° antibody were used to
determine an optimum dilution.
Dilution of eNOS ab 
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■ I
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The results from this experiment suggest that a 1:2000 dilution of eNOS primary 
antibody and a 1:15,000 dilution of anti-rabbit 2° antibody will produce a maximum 
signal for eNOS from 10 ¡xg of BAEC whole cell lysate.
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3 3 .2  Optimisation o f the Cox I primary antibody
The Cox 11° antibody was optimised using the dot blot apparatus as described in 
section 2.2.8. Briefly, the experiment was carried out in a similar fashion to that of the 
eNOS 1° antibody described in section 3.2.1.
The results were as follows:
Figure 3.3.2 Results from dot blot immunoassay with 10|xg of BAEC whole cell
lysate. Various concentrations of Cox I 1° antibody were used to
determine an optimum dilution.
Dilution of eNOS ab 
1:100 1:200 1:500 1:1000 1:2000
§5
o
I
13o• H
a ,O
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The results from this experiment suggest that a 1:100 dilution of Cox I primary antibody 
and a 1:8000 anti-mouse 2° antibody dilution will produce a strong, but not maximal, 
signal for Cox I from 10 ¡xg of BAEC whole cell lysate. The signal intensity did not 
plateaux with this range of 1° antibody and so a dilution lower than 1:100 may have 
given a stronger signal.
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3.4 Summary o f Results
A summary of the optimised conditions determined for RT-PCR and Western 
lmmunoblot is presented here. The conditions for each primer set were determined 
empirically in order that semi-quantitative comparisons could be made between 
samples. The following conditions were used throughout the rest of the study:
Table 3.4: A summary of the empirically determined conditions employed
for each primer set used in RT-PCR.
Cox I Cox II eNos GAPDH P-actin
Initial RNA 
concentration
1 ^g* 0.2 |xg 0.5 ng 0.2 jig
Volume of 
MgCl2 
(25 mM)
3 p.1 3 jil 3 (il 3 |wl 3 yil
Number of 
PCR cycles
35 40 25 25 25
Annealing
temperature
55°C" 55°C" 55°C" 55°C” 55°C"
* The Cox II primer set was used qualitatively, not quantitatively and so the initial 
amount of RNA used did not need to be determined.
**Primers were designed with -50% GC content so the annealing temperature for all 
sets was ~55°C.
The optimal conditions employed for western immunoblot were also determined and are
as follows:
• A 1:100 dilution of Cox I primary antibody and a 1:8000 dilution of anti-mouse 
2° antibody will produce a strong, but not maximal, signal for Cox I from 10 (ig 
of BAEC whole cell lysate.
• A 1:2000 dilution of eNOS primary antibody and a 1:15,000 dilution of anti­
rabbit 2° antibody will produce a maximum signal for eNOS from 10 ¡xg o f 
BAEC whole cell lysate.
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Chapter 4 The Effects of CLA on BAEC Function
4.1 Introduction
The effect of CLA isomer mix on steady state mRNA levels, protein expression and 
activity of Cox I, Cox II and eNOS in BAEC is reported in this chapter. The importance 
of correctly regulated expression and activity of these enzymes with regard to the 
vasoregulatory mechanisms of the vascular endothelium has already been discussed, 
section 1.1. The pretext for this study has been outlined in detail in section 1.2. Briefly, 
the results from a number of in vivo studies have shown that CLA may have an 
atheroprotective effect on the vasculature, through slowing the development of 
atherosclerotic plaque (Lee et al, 1994). It has been postulated that the effect is elicited 
via at least two potential mechanisms.
Firstly, by modulating endothelium exposure to oxidative stress. It has been shown that 
CLA may be oxidised to several furan derivatives that possess an oxidation/reduction 
buffering capacity (Yurawecz et al, 1995). It is postulated that this property of CLA 
may effect the expression and/or activity of eNOS through alteration of oxidative 
processes. Secondly, it has been shown that CLA is incorporated into fatty acid profile 
of the cell membrane and subsequently alters eicosanoid metabolism (Ha et al, 1990). 
This has previously been proven for a venous cell type although no data was presented 
for CLAs effect on Cox mRNA or protein expression (Urquhart et al, 2001). It is 
therefore hypothesised that CLA will putatively affect expression or activity of eNOS 
and/or Cox I in BAECs.
The experiments were designed to examine the effects of chronic treatments (up to 24 
hours) of the CLA mix (0-10 |.ig/ml) on the expression of eNOS and Cox I protein and 
steady state RNA. The effect of CLA treatment on production of PGF[a from un­
stimulated BAEC was examined as was the effect of treatment on nitrite levels in 
conditioned media generated from un-stimulated and agonist stimulated BAEC. The 
rational behind examining the effect of CLA on agonist stimulated eNOS activity was 
that CLA treatment seemed to elicit no response in unstimulated BAEC. This is further 
explained in section 4.3.3.
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4.2 The effect o f CLA on eNOS expression
4.2.1 Dose dependent effect of CLA mix treatment on eNOS protein 
expression
To determine whether various concentrations of the CLA mix and LA had any effect 
eNOS protein expression, BAEC were incubated with 0-10 fxg/ml of CLA mix and LA 
for 24 hours. It was found that concentrations over 10 jj,g of CLA resulted in cells that 
morphologically looked very unhealthy. A larger quantity of floating cells were also 
noted at concentrations above 10 (ig.
Stretched BAEC (5%) were used as positive control for the up regulation of eNOS. 
BAEC were stretched as described in section 2.2.14. Whole cell lysates were prepared 
as described in section 2.2.3. SDS PAGE and western blot analysis was carried out as 
described in section 2.2.9.
Linoleic acid was used as control to determine whether the conjugation of the CLA 
isomers was eliciting any effects on eNOS protein expression. Because all the 
treatments were dissolved in 95% ETOH, a vehicle control was included. The volumn 
of vechile control (95% ETOH) was the same as the treatment for all CLA treatments 
reported in this chapter.
The cells were quiesced for 24 hours before being treated. This was to ensure that the 
cells were all at G0 of the cell cycle before treatment.
The results were as follows:
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Figure 4.2.1 Fold change in eNOS protein expression in BAEC after 24 hour 
treatment with 0-10 (xg/ml CLA mix and LA as determined by western 
blot analysis. BAEC were quiesced by serum deprivation for 24 hours 
prior to treatment. Equality of protein loading was determined by 
Ponceau staining. The image presented is representative. The graph 
shown is derived from mean densitometric analysis of results from 
multiple analysis of samples generated from three separate experiments.
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The results from this experiment suggest that CLA mix, at 0-10 |ag/ml, had no effect on 
the expression of eNOS in BAEC at 24 hours. 10 (xg/ml was also determined to be a 
maximum concentration for treatment due to the toxic effects of higher concentrations.
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4.2.2 The efect of, CLA isomer tl0/cl2, CLA mix and Linoleic acid on 
eNOS protein expresion
To determine whether the CLA isomer tl0/cl2 elicited any effect on eNOS compared to 
CLA mix and linoleic acid, BAEC were treated with 10 (xg/ml for 24 hours. Because all 
the treatments were dissolved in 95% ETOH, a vehicle control was included. The 
volumn of vechile control (95% ETOH) was the same as the treatment for all CLA 
treatments reported in this chapter. Whole cell lysates were prepared as described in 
section 2.2.3. SDS PAGE and western blot analysis was carried out as described in 
section 2.2.9
Figure 4.2.2 Fold change in eNOS protein expression in BAEC after treatment for 24 
hours with CLA mix, CLA isomer tl0/cl2, linoleic acid and ETOH 
control. BAEC were quiesced by serum deprivation for 24 hours prior to 
treatment. Equal protein loading was determined by Ponceau staining. 
The image presented is representative. The graph shown is derived from 
mean densitometric analysis of results from multiple analysis of samples 
generated from two separate experiments.
E T O H  contro l L A  10ng/m l Isom er 10/12 10 |ig /m l C L A  10 (ig /m l
E T O H  contro l L A  10 |ig /m l Isomer 10/12 10 jig /m l C L A  10 (ig/m l
The results from this experiment suggest that CLA isomer tl0/cl2, at 10 |ig/ml, had no 
effect on eNOS protein expression in BAEC at 24 hours compared to CLA mix and 
linoleic acid.
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4.2.3 Temporal efect of CLA mix treatment on eNOS protein expresion 
To determine the effect of the CLA mix on eNOS protein expression over time, BAEC 
were incubated with 10 (ig/ml of CLA mix over a time course up to 24 hours. Whole 
cell lysates were prepared as described in section 2.2.3. SDS PAGE and western blot 
analysis was carried out as described in section 2.2.9.
Figure 4.2.3: Fold change in eNOS protein expression in BAEC over a time course
after treatment with CLA mix. BAEC were quiesced by serum
deprivation for 24 hours prior to treatment. Equality of protein loading 
was determined by ponceau staining. The image presented is
representative. The graph shown is derived from mean densitometric 
analysis of results from multiple analysis of samples generated from two 
separate experiments.
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The results from this experiment suggest that 10 (og/ml of CLA mix had no effect on
eNOS expression in BAEC over a 24 hour time course.
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4.2.4 The effect of CLA mix on eNOS steady state mRNA levels in BAEC
To determine the effect of CLA mix on eNOS mRNA transcription, BAECs were 
treated with a single concentration of the mix for 24 hours. Total RNA was harvested by 
using the Trizol® method as described in section 2.2.5, RT-PCR was carried out as 
described in section 2.2.10. Control primers and control RNA was used for the +RT 
control, this was included as a positive control for the technique. A -RT control was 
included to ensure that amplification was not due to contaminating genomic DNA.
Figure 4.2.4 Fold change in eNOS mRNA in BAEC after 24 hours of treatment with 
10 |j.g/ml CLA mix. BAEC were quiesced by serum deprivation for 24 
hours prior to treatment. Results were normalised by amplification of P- 
actin. The image presented is representative. The graph shown is derived 
from mean densitometric analysis of results from multiple analysis of 
samples generated from four separate experiments.
D N A  eN O S  p ac tin
L a d d e r  C L A  lO u g /m l E T O H  co n tro l C L A lO u g /m l E T O H  c o n tro l + R T  -R T
E thano l con tro l C L A  tre a tm e n t
The results from this experiment suggest that 10 |jg/ml of CLA mix had no effect on
eNOS steady state mRNA levels in BAEC at 24 hours.
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4.3.1 The efect of acute CLA mix treatment on nitrite levels in 
conditioned media from unstimulated BAEC
4.3 The effect of CLA mix treatment on eNOS activity
The effect of treatment on eNOS activity was determined by measuring the amounts of 
nitrite in conditioned media. eNOS produces nitric oxide which is rapidly converted to 
both nitrite and nitrate. Measurement of nitrite is an indirect index of eNOS activity. 
Nitrite was measured by the fluorometric DAN assay section 2.2.12. As a positive 
control for the assay conditioned media from Calcium Ionophore A23187 treated BAEC 
was assayed. Calcium ionophore treatment stimulates eNOS activity through a transient 
increase in cellular Ca2+. The determined effects of CLA mix on eNOS activity over a 3 
hour time course was follows:
Figure 4.3.1 Change in nitrite levels in conditioned media after treatment with CLA 
10 |j,g/ml, ETOH control, and Calcium Ionophore A23187 10 (oM. The 
graph shown is derived from mean statistical analysis of results from 
multiple analysis of samples generated from a least three separate 
experiments. * P<0.05 versus ETOH Control.
-ETOH
-CLA
- Calcium Ionophore
Tim e (m in)
The results from this experiment suggest that CLA mix 10 (ig/ml had no effect on the
basal activity of eNOS over a 3 hour time course.
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Because there seemed to be no effect o f  CLA m ix on eNOS activity over an acute time 
course, it was decided to examine the effects over a chronic time course. The 
determined effects o f  chronic exposure o f  CLA m ix on basal eNOS activity was as 
follows:
4.3.2 The effect of chronic CLA mix treatment on nitrite levels in conditioned
media from unstimulated BAEC
Figure 4.3.2 Change in nitrite levels in conditioned media after treatment with CLA 
10 |xg/ml and ETOH control over a chronic time course. The graph 
shown is derived from mean statistical analysis o f results from multiple 
analysis o f  samples generated from a least three separate experiments.
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The results from this experiment suggest that CLA mix 10 (ig/ml had no effect on the 
basal activity o f  eNOS over a 72 hour time course.
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4.3.3 The effect of acute CLA mix pre-treatment on Bradykinin stimulation of 
eNOS by measurement of nitrite levels in conditioned media
Because CLA mix did not exert any effect on the activity of basal eNOS activity, it was 
decided to investigate the effect of CLA pre-treatment, both chronic and acute, on the 
ability of Bradykinin to stimulate eNOS activity. Bradykinin stimulates eNOS through a 
receptor mediated increase in cellular Ca2+. After CLA mix treatment (10 |Jg/ml) for 3 
hours, the CLA containing media was removed and BAEC were stimulated with 5 ¡¿M 
of Bradykinin in fresh media. Conditioned media was then harvested over a 3 hour time 
course and assayed for nitrite by the DAN fluorometric method as an index of eNOS 
activity. The negative control represents non stimulated nitrite build up over 3 hours. 
The results were as follows:
Figure 4.3.3 Change in nitrite levels in conditioned media over time. The graph 
shown is derived from statistical analysis of results from triplicate 
analysis of samples generated from two separate experiments. * P<0.05 
versus BK Control. ** P<0.05 versus Negative control.2 n
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I
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The results from this experiment suggest that a 3 hour pre-treatment with 10 ¡xg/ml CLA 
mix potentates the stimulation of eNOS in BAEC by bradykinin over a 3 hour time 
course.
62
Fo
ld 
ch
an
ge
 
re
lat
iv
e 
to 
co
nt
ro
lh
This experiment was carried out to determine whether CLAs effect on bradykinin 
stimulation of eNOS occurred with a chronic pre-treatment. After CLA mix treatment 
for 24 hours, BAEC were stimulated with 5jjM  of Bradykinin in fresh media. 
Conditioned media was then harvested over a 3 hour time course and assayed for nitrite 
by the DAN fluorometric method as an index of eNOS activity. The negative control 
represents nitrite build up without any treatment. The results were as follows:
Figure 4.3.4 Change in nitrite levels in conditioned media over time. The graph 
shown is derived from mean statistical analysis of results from triplicate 
analysis of samples generated from two separate experiments * P<0.05
4.3.4 The effect of chronic CLA mix treatment on nitrite levels in conditioned
media after stimulation of BAEC with Bradykinin
Time min.
The results from this experiment suggest that a 24 hour pre-treatment with 10 |j.g/ml 
CLA mix potentates the stimulation of eNOS in BAEC by bradykinin over a 3 hour 
time course.
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4.4 The effect of CLA mix on Cyclooxygenase expression
4.4.1 Dose dependant effect of CLA mix treatment on Cox I protein expression
In order to determine the effect of various concentrations of the CLA mix on Cox I 
protein, BAEC were incubated with between 0-10 jig/ml of the mix for 24 hours. BAEC 
that had been exposed to 5% stretch (as described in section 2.2.14) were also prepared 
as positive controls for the up regulation of Cox I protein. Whole cell lysates were 
prepared as described in section 2.2.3. SDS PAGE and western blot analysis was carried 
out as described in section 2.2.9.
Figure 4.4.1 Fold change in Cox I protein expression in BAEC after 24 hour treatment with 0-10 
Hg/ml of CLA mix. BAEC were quiesced by serum deprivation for 24 hours prior to 
treatment. Equality of protein loading was determined by ponceau staining. The image 
presented is representative. The graph shown is derived from mean densitometric 
analysis o f results from multiple analysis of samples generated from three separate 
experiments.
CLA mix p.g/ml 
5 10 Stretch control 0% High stretch 5%
k
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* * _ 1
10 S tre tch  contro l H ig h  S tre tch
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The results from this experiment suggest that 10 |ig/ml of CLA mix had no effect on the
expression of Cox I in BAEC at 24 hours.
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4.4.2 The efect of CLA mix on Cox I steady state mRNA levels
To determine the effect of the CLA mix on Cox I steady state mRNA levels, BAEC
were incubated with a single concentration of the mix for 24 hours. Samples generated
_ _ r\ f
from BAEC exposed to shear stress (23 dyn/cm , as described in section 2.2.15) were 
used as positive controls for the up regulation of Cox I mRNA. Cox I cDNA was 
amplified as a positive control for the Cox I primer set. Total RNA was harvested by 
using the Trizol® method, section 2.2.5. RT PCR was carried out as described in section
2.2.10.
Figure 4.4.2 Fold change in Cox I mRNA in BAEC after 24 hour treatment with 10 
(xg/ml CLA BAEC were quiesced by serum deprivation for 24 hours 
prior to treatment. Results were normalised by amplification of (3-actin or 
GAPDH. The image presented is representative. The graph shown is 
derived from mean densitometric analysis of results from multiple 
analysis of samples generated from four separate experiments.
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N e g a tiv e  R T  c o n tro l C L A  E T O H  oon tro l L a d d er
G A P D H  P C R  P ro d u o ts  
L o w  s h e a r  0.5 d y n /cm 2 H ig h  sh e a r  23  d y n /om 2
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ETOH CLA low shear high shear
The results from this experiment suggest that 10 |jg/ml of CLA mix had no effect on the 
expression of Cox I mRNA in B AECs at 24 hours.
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To determine whether CLA mix had any effect on Cox II steady state mRNA levels, 
BAEC were incubated with a 10 jj,g/ml of the mix for 24 hours. Samples generated from 
BAEC exposed to cyclic stretch (5%) were used as positive controls for the up 
regulation of Cox II mRNA. Total RNA was harvested by using the Trizol® method as 
described in section 2.2.5. RT PCR was carried out as described in section 2.2.10.
Figure 4.4.3 Fold change in Cox II mRNA in BAEC after 24 hour treatment with 10 
pg/ml CLA. BAEC were quiesced by serum deprivation for 24 hours 
prior to treatment. Results were normalised by amplification of GAPDH.
The image presented is representative. The graph shown is derived from 
mean densitometric analysis of results from multiple analysis of samples 
generated from two separate experiments.
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4.4.3 The effect of CLA mix on Cox II steady state mRNA levels
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The results from this experiment suggest that 10 ¡jg/ml CLA mix had no effect on the
induction of Cox II transcription in BAEC after 24 hours.
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4.5 The effect of CLA on Cyclooxygenase activity
4.5.1 Dose dependant efect of CLA mix on 6-keto-Prostaglandin Fia levels 
in conditioned media after 24 hours
6-keto-Prostaglandin Fia a stable downstream product of the cyclooxygenase pathway. 
The rate limiting enzyme of this pathway is Cox I. Cox I enzyme activity can be 
measured indirectly by monitoring the production of 6-keto-Prostaglandin Fia. The 
effects of the CLA mix on Cox I activity was indirectly measured by ELISA The 
results were as follows.
Figure 4.5.1 Change in 6-Keto PGI Fia concentration in conditioned media after 24 
hour treatment with 0-10 |j,g/ml CLA mix as determined by ELISA. Cells 
were quiesced by serum starvation prior to treatment. The graph shown 
is derived from mean statistical analysis of results from triplicate 
analysis of samples generated from three separate experiments. * P<0.05 
versus ETOH control
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The results from this experiment suggest that CLA mix decreases the production of 6- 
Keto PGI Fia with increasing dose at 24 hours. This is suggestive of a decrease in the 
production of PGL and possibly a decrease in cyclooxygenase activity.
*
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CLA mix (xg/ml
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4.5.2 The efect of acute CLA mix treatment on 6-keto-Prostaglandin Fia levels in 
conditioned media
To determine whether the decrease in the production of 6-keto-Prostaglandin Fia caused 
by CLA occurred over an acute time course the following experiments were carried out. 
The dose of 10 ¡ig/ml was chosen because it elicited the strongest response. The levels 
of 6-keto-Prostaglandin Fia in conditioned media was measured by ELISA as described 
in section 2.2.11. The results were as follows:
Figure 4.5.2 Change in 6-Keto PGFia concentration in conditioned media after acute 
CLA mix treatment. Cells were quiesced by serum starvation prior to 
treatment. The graph shown is derived from mean statistical analysis of 
results from triplicate analysis of samples generated from two separate 
experiments * P<0.05 versus ETOH control. ** P<0.05 versus 0 min.
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The results from this experiment suggest that CLA mix decreases the production of 6- 
Keto PGFia over a 3 hour time course. Again, this is suggestive of a decrease in the 
production of PGI2 and possibly a decrease in cyclooxygenase activity. The increase in 
PGFia after ETOH treatment is a result of natural build in the media.
CLA
ETOK
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4.5.3 The effect of chronic CLA mix treatment on 6-keto-Prostaglandin Fi„ levels 
in conditioned media
To determine whether the decrease in the production of 6-keto-Prostaglandin Fia caused 
by CLA occurred over a chronic time course the following experiment was carried out. 
The dose of 10 (xg/ml was chosen because it elicited the strongest response. The results 
were as follows:
Figure 4.5.3 Change in 6-Keto PGFia concentration in conditioned media after 
chronic treatment with CLA mix . Cells were quiesced by serum 
starvation prior to treatment. The graph shown is derived from mean 
statistical analysis of results from triplicate analysis of samples generated 
from two separate experiments * P<0.05 versus ETOH control. ** 
P<0.05 versus 0 min
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The results from this experiment suggest that CLA mix decreases the production of 6- 
Keto PGI Fia over a 72 hour time course. The increase in PGFia after ETOH treatment is 
a result of natural build in the media. Again, this is suggestive of a decrease in the 
production of PGI2 and possibly a decrease in cyclooxygenase activity.
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The results from this study demonstrate that CLA has no dose dependant or temporal 
effect on eNOS protein expression, or steady state mRNA levels after 24 hours, under 
non-agonist stimulated conditions. The CLA isomer tl0/cl2 has been shown to posses 
distinct biological activity compared to other isomers of CLA (Khosla and Fungwe, 
2001). The 110/c 12 isomer also showed no regulation of eNOS protein expression. As a 
control for the conjugation of CLA, linoleic acid was also tested, and also had no effect 
on eNOS protein. Treatment also had no impact on basal levels of eNOS activity over 
an acute and chronic time course. Subsequently it was decided to examine whether CLA 
affected agonist-stimulated eNOS activity. Pre-treatment with CLA was shown to 
synergistically augment agonist activation of eNOS. Following pre-treatment of BAEC 
with CLA mix for 3 and 24 hours, Bradykinin stimulated release of nitric oxide was 
increased up to 28% relative to controls, for both treatments. These events are 
illustrated in the proposed model shown below.
•  Unstimulated
4.6 Discussion
Ca
C
Ca
Bradykinin in plasma mainly acts on endothelial cells and stimulates them to release 
various agents associated with vascular tone and blood coagulation, such as nitric oxide, 
prostaglandin’s, catecholamines, and cytokines, resulting in the maintenance of 
circulatory homeostasis (Dendorfer et al, 1998). Most of the cellular action of 
bradykinin are mediated through binding to the B2 receptor (Figure 4.6). Bradykinin 
stimulation of BAECs causes a release of Ca2+ from intracellular mitochondria stores 
and a Ca2+ influx from outside the cell. Both, release and influx of Ca2+ lead to a 
transient increase in cytosolic Ca2+, which promotes the binding of calmodulin (CaM) to 
eNOS. Subsequent phosphorylation, coupling with Heat Shock Protein 90 (Hsp 90) and 
release of eNOS from Caveolin-1 leads to enzyme activation and nitric oxide release. 
eNOS also forms complexes with the bradykinin B2 receptor, inhibiting activation, 
from which the enzyme is released in a Ca2+ and ligand-dependent manner upon B2 
receptor activation (Venema, 2002). This is a common and significant form of eNOS 
regulation.
The role that CLA would have in augmenting this activation is unclear. CLA is 
incorporated into the phospholipid profile of the cell membrane (Belury and Kempa- 
Steczko, 1997). It could be possible that the altered lipid profile affects the 3D structure 
of the B2 receptor resulting in a higher affinity for bradykinin and/or decreased affinity 
for inhibitory binding of eNOS, both of which would lead to increased nitric oxide 
production. This is speculative and needs further investigation. Such a study would 
initially need to examine whether CLA augmented receptor-independent activation in a 
similar manner. CLA may also alter the calcium influx elicited by bradykinin 
stimulation. Arachidonic acid, another cell membrane lipid, has previously been show 
to putatively modulate ion channel function (Devor and Frizzell, 1998). A previous 
study showed that in cultured keratinocytes, CLA reduced the incorporation of C14- 
arachidonate (Liu and Belury, 1998).
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eNos remains in an inactive state through binding to plasmalemmal caveolae (caveolin- 
1 and -3) (Andrew and Mayer, 1999). The distinctive lipid content of the caveolae is 
vital to the inhibitory function of Caveolin-1. A study carried out by Venema et al,
(1995) demonstrated that eNOS activity could be negatively modified, through 
alteration of binding to caveolin-1, by anionic phospholipids present in the cell 
membrane. CLA present in the cell membrane may also modulate this inhibitory 
binding mechanism and therefore augment bradykinin-stimulated activation.
This synergistic augmentation of nitric oxide production may also be associated with 
other endothelial cell activators not examined in this study. CLA may have the same 
effect with Ca2+ independent activation by shear stress and cyclic strain, or by G-protein 
receptor independent activation by calcium ionophore A23187. Other eNOS activators 
that could be examined would include vascular endothelial growth factor (VEGF), 
acytlecholine and substance P.
CLA may also be modulating the availability of NO once it is released from the cell. 
The half life of NO is very short, on the order of seconds (Wink et al, 1998). NO reacts 
with 0 2 to form various reactive NO species, as well as nitrite and nitrate (Kim et al, 
2001). Because CLA may possess redox buffering capacity, it may be modulating the 
kinetics of these breakdown reactions resulting in higher available nitrite 
concentrations. Overall there are a number of different ways CLA could be eliciting the 
observed augmentation of bradykinin stimulated eNOS.
The second mechanism of action which may be eliciting the atheroprotective effects of 
CLA involves modulation of the cyclooxygenase pathway under non-stimulated 
conditions. The results demonstrate that CLA has no effect on Cox I steady state mRNA 
levels and protein expression. CLA did however down regulate the release of 6-Keto 
PGF la (a stable metabolite of PGI2) in a time (60% decrease after 72 h) and dose (60% 
decrease with 10 (xg/ml after 24 h) dependent manner. This down regulation of 
prostacyclin (PGI2) suggests an inhibition of the cyclooxygenase pathway, consistent 
with this observation is a previous study which shows that CLA affects arachidonic acid
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metabolism in human saphenous vein endothelial cells, inhibiting eicosanoid production 
(Urquhart, 2001).
There are a number of mechanisms by which CLA may be eliciting this effect. Like 
most other dietary polyunsaturated fatty acids, isomers and metabolites of CLA are 
readily incorporated into phospholipid and neutral lipid fraction of the cell membrane 
(Belury and Kempa-Steczko, 1997). This incorporation could be in competition with the 
uptake of linoleic acid, the precursor of arachadonic acid. Arachadonic acid is the 
natural substrate of the Cox pathway. This competition may have the effect of reducing 
the arachadonic acid complement of the cell membrane, which would subsequently 
cause a decrease in Cox activity and PGH2 production (Belury, 2002). A previous study 
showed that in cultured keratinocytes, CLA reduced the incorporation of C14- 
arachidonate (Liu and Belury, 1998). Another theory raises the possibility that CLA or 
elongated and desaturated products from CLA may act as substrates or antagonists for 
cyclooxygenase, resulting in reduced available enzyme for arachidonate. If CLA is 
metabolised by Cox it may give rise to a new profile of CLA derived eicosanoids 
(Belury, 2002).
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Chapter 5 The Effect of DL Homocysteine on BAEC function
5.1 Introduction
The effects of the non protein amino acid homocysteine on steady state mRNA levels, 
protein expression and activity of eNOS enzyme is reported in this chapter. The 
importance of correct expression and activity of eNOS with regard to the 
vasoregulatory mechanisms of the vascular endothelium has already been discussed, 
section 1.1. The pretext for this study has previously been described in section 1.3.
Briefly, homocysteine has previously been shown to interfere with the availability of 
nitric oxide produced by the vascular endothelium. Homocysteine interacts with nitric 
oxide to produce S-nitrosohomocysteine at physiological concentrations, which 
amplifies the vasoprotective effects of nitric oxide. Normal endothelial cells detoxify 
homocysteine by releasing nitric oxide (Stamler et al, 1993), which in turn leads to the 
formation of S-nitrosohomocysteine. This reaction decreases the production of 
hydrogen peroxide following oxidation of sulphydryl groups and represents a protective 
mechanism against the adverse effects of homocysteine. Although prolonged exposure 
and high homocysteine concentrations result in impaired nitric oxide production. 
Therefore chronically elevated homocysteine concentrations appear to cause a self- 
perpetuating cycle that eventually overwhelms the capacity of the endothelial cells to 
reduce the toxicity of homocysteine (Stamler et al, 1993).
From this pretext it is proposed that homocysteine may play a role in modulating the 
expression/ activity of eNOS protein and mRNA. The experiments were designed to 
examine the effects of chronic treatments (up to 24 hours) of the homocysteine (0-500 
[iM) on the expression of eNOS protein and steady state RNA. The effect of 
homocysteine treatment on nitrite levels over acute (0-3 hours) and chronic (0-72 hours) 
in conditioned media generated from un-stimulated BAEC was also investigated. 
Modulation of cyclooxygenase expression and activity was not investigated as there 
was not a strong pretext for such a study.
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5.1.1 Dose dependent efect of DL - homocysteine treatment on eNOS 
protein expresion
To determine the effect of various concentrations of homocysteine on eNOS protein 
expression, BAEC were incubated with 0-500 jjM  of Hey for 24 hours. Stretched 
BAECs (5%) were used as positive control for the up regulation of eNOS. BAEC were 
stretched as described in section 2.2.14. Whole cell lysates were prepared as described 
in section 2.2.3. SDS PAGE and western blot analysis was carried out as described in 
section 2.2.9.
Figure 5.1.1 Fold change in eNos protein expression in BAEC after 24 hour treatment 
with various doses of Hey. Cells were quiesced by serum deprivation for 
24 hours prior to treatment. Equality of protein loading was determined 
by ponceau staining. The image presented is representative. The graph 
shown is derived from mean densitometric analysis of results from 
multiple analysis of samples generated from three separate experiments.
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2.50 
2.00
1.50 
1.00 
0.50 
0.00 . J i .
m
0.5
_ I
1 100 500 High Stretch
stretch control
5% 0%
5 10 50
Hey conc.(jM
The results from this experiment suggest that 0-500 |jM  DL-homocysteine has no effect 
on the expression of eNOS protein in BAEC after 24 hours.
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5.1.2 The efect of DL - homocysteine and homocysteine thiolactone 
treatment on eNOS protein expresion
Because no effect was observed for DL - homocysteine, it was decided to examine the 
effects of homocysteine thiolactone on the expression of eNOS protein. Homocysteine 
thiolactone is a thiol form of circulating homocysteine that is also implicated in 
cardiovascular disease. A concentration of 80 ¡jM  was chosen because it is relevant to 
pathophysiological levels in a patient with hyperhomocysteine The results were as 
follows:
Figure 5.1.2 Fold change in eNOS in bovine aortic endothelial cells after 24 hour 
treatment with Hey and Hey Thio. Cells were quiesced by serum 
deprivation for 24 hours prior to treatment. Equality of protein loading 
was determined by ponceau staining. The image presented is 
representative The graph shown is derived from mean densitometric 
analysis of results from multiple analysis of samples generated from two 
separate experiments.
Control Hey Thio 80pM Hey 80pM
Neg cont. Thio 80 piM Hey 80
The results of this experiment suggest that 80 (iM of DL - homocysteine and 
homocysteine thiolactone did not effect eNOS expression in BAEC after 24 hours.
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5.1.3 Temporal efect of homocysteine treatment on eNOS protein 
expresion
To determine the effect of homocysteine treatment on eNOS protein expression with 
respect to time, BAEC were incubated with a pathophysiological relevant concentration 
of Hey, 80 pM, over a 72 hour period. Whole cell lysates were prepared as described in 
section 2.2.3. SDS PAGE and western blot analysis was carried out as described in 
section 2.2.9. The results were as follows:
Figure 5.1.3 Fold change in eNOS protein expression relevant to control in BAEC, 
over a 72 hour period. Cells were quiesced by serum deprivation for 24 
hours prior to treatment. Equality of protein loading was determined by 
ponceau staining. The image presented is representative. The graph 
shown is derived from mean densitometric analysis of results from 
multiple analysis of samples generated from two separate experiments.
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The results from this experiment suggest that 80 pM DL - homocysteine has no 
temporal effect on eNOS protein expression over a 24 hour period in BAEC.
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To determine whether Hey had any effect on eNOS mRNA transcription BAEC were 
treated with 80 (jM of Hey for 24 hours. Total RNA then harvested by the Trizol® 
method as described in section 2.2.5. RT PCR was carried out as described in section
2.2.10. The results were as follows:
Figure 5.1.4 Fold change in eNOS mRNA in BAECs after 24 hours of treatment with 
Hey 80|jM as determined by RT-PCR. Cells were quiesced by serum 
deprivation for 24 hours prior to treatment. Results were normalised by 
amplification of (3-actin. The image presented is representative. The 
graph shown is derived from mean densitometric analysis of results from 
multiple analysis of samples generated from two separate experiments.
(3-actin eNOS
Negative Control Hey 80 |jM  Negative Control Hey 80 pM
5.1.4 The effect of DL - homocysteine on eNOS steady state mRNA levels
2 1 
1.5 -
1
0.5 -
Negative control Hey 80mM
The results from this experiment suggest that 80 jjM  of DL - homocysteine have no 
effect on eNOS mRNA expression in BAEC after 24 hours.
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5.2.1 The efect of acute DL - homocysteine treatment on nitrite levels in 
conditioned media of unstimulated BAEC
The effect of treatment on eNOS activity was determined by measuring the amounts of 
nitrite in conditioned media. eNOS produces nitric oxide which is rapidly converted to 
both nitrite and nitrate. Measurement of nitrite is an indirect index of eNOS activity. 
Nitrite was measured by the fluorometric DAN assay section 2.2.12. As a positive 
control for the assay conditioned media from Calcium Ionophore A23187 treated BAEC 
was assayed. Calcium ionophore treatment stimulates eNOS activity through a transient 
increase in cellular Ca2+. The determined effects of DL - homocysteine on basal eNOS 
activity over a 3 hour time course was follows:
Figure 5.2.1 Change in nitrite levels in conditioned media after treatment with Hey 80 
pM, and Calcium Ionophore 10 ¡jM over a three hour time course as 
measured by the DAN fluorometric assay. The graph shown is derived 
from mean statistical analysis of results from multiple analysis of 
samples generated from three separate experiments.
5.2 The effect of DL - homocysteine on eNOS enzyme activity
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The results from this experiment suggest that DL - homocysteine has no effect on the
basal activity of eNOS over a 3 hour time course.
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5.2.2 The effect of chronic DL - homocysteine treatment on nitrite levels 
in conditioned media
Because there seemed to be no effect of homocysteine on eNOS activity over an acute 
time course, it was decided to examine the effects over a chronic time course. The 
determined effects of chronic exposure of Homocysteine on basal eNOS activity was as 
follows:
Figure 5.2.2 Change in nitrite levels in conditioned media after treatment with Hey 80 
(jM over a seventy two hour time course as measured by the DAN 
fluorometric assay. The graph shown is derived from mean statistical 
analysis of results from multiple analysis of samples generated from 
three separate experiments.
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The results from this experiment suggest that DL - homocysteine has no effect on the
basal activity o f eNOS over a 72 hour time course.
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5.3 Discussion
The second aspect of this study focuses on homocysteine. The pretext for studying the 
effects of homocysteine was that it deleteriously modulates extra cellular 
oxidation/reduction processes.
Homocysteine has previously been shown to limit the availability of nitric oxide 
produced by the vascular endothelium. Normal endothelial cells detoxify homocysteine 
by releasing nitric oxide (Stamler et al, 1993), which in turn leads to the formation of S- 
nitrosohomocysteine. Acutely, and at low concentrations, this has the effect of 
improving the vasodilation function of the endothelium. However, at higher 
concentrations and with chronic exposure, bio availability of nitric oxide is drastically 
decreased, which is severely deleterious to endothelial vasodilatory function.
We subsequently hypothesized that homocysteine treatment may cause up regulation of 
expression or activity of eNOS to compensate for the lower levels of nitric oxide 
available to the vascular endothelium.
The results presented in this study suggest that DL - homocysteine treatment of BAEC 
has no effect on steady state mRNA levels and protein expression or activity of eNOS 
over acute and chronic time courses. Protein levels of eNOS were unaffected by DL - 
homocysteine and homocysteine thiolactone treatment at physiological and 
pharmacological concentrations. Nitrite levels in conditioned media remained 
unchanged after chronic and acute treatments.
One limitation of this study is the form that the homocysteine is presented to the cells. 
In vivo, homocysteine exists in a number of conjugated forms. A small fraction (<2%) 
of plasma total homocysteine circulates in the thiol form. The remainder is a mixture of 
disulfide derivatives, including homocystine, homocysteine-cysteine mixed disulfide, 
and protein bound disulfides (Mudd et al, 2000). It is possible that in vivo these forms 
may affect regulation of eNOS. In a human study by Chambers et al, (2001) it was 
demonstrated that reduced homocysteine is the deleterious form of homocysteine with
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regards to vascular function and that other homocysteine species play a less important
Many of the studies to date have examined the effects of pharmacological 
concentrations of homocysteine, which is not accurately representative of the situation 
in vivo. For further in vitro studies it would be interesting to present a reduced 
homocysteine treatment, at physiological concentrations, to BAEC and then examine 
the effects on vasoregulatory function. This kind of treatment would need a validated 
manipulation of the oxidation status of the culture media to produce the desired reduced 
homocysteine.
A study carried out by Zhang et al, (2000) corroborates the non effect of homocysteine 
on eNOS expression presented here. The group did, however, report that pre-treatment 
with homocysteine resulted in a gradual decline in bradykinin, calcium ionophore and 
L-arginine stimulated nitric oxide production. An increase in reduced oxygen species 
was also reported with pre-treatment. A lack of consensus still exists, however, as to the 
effects of homocysteine on nitric oxide production. A study by Upchurch et al, (1997) 
report that homocysteine stimulates nitric oxide production, while De Groote et al,
(1996) suggest that homocysteine downregulates nitric oxide production.
Whether or not homocysteine modulates eNOS activity, homocysteine does adversely 
affect endothelial function by modulating exposure to oxidative stress. A depletion in 
bioavailable nitric oxide, through alteration of oxidative stress has been reported 
(Stamler et al, 1993). Auto-oxidation of homocysteine results in the production reactive 
oxygen species such as of hydrogen peroxide and superoxide ion (Heinecke et al, 
1987). Superoxide anion can react with nitric oxide to form peroxynitrite, which impairs 
its biological activity (Gryglewski, 1986). The role of superoxide formation in 
homocysteine-induced endothelial dysfunction is underscored by the demonstration of 
greater superoxide production in aortic tissue from mildly hyperhomocysteinemic mice 
than from wild-type mice (Eberhardt, 2000) and the finding that superoxide dismutase 
can reverse the decreased cerebrocortical blood flow during superfusion with 
homocysteine-containing buffer (Zhang, 1998). Earlier investigations have supported a
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role for H2O2 in homocysteine-induced endothelial toxicity in vitro because catalase was 
found to inhibit the homocysteine-induced lysis of endothelial cells in the presence of 
transition metals or ceruloplasmin (Starkbaum, 1986).
Homocysteine-induced vascular oxidant stress may be additionally aggravated by a 
homocysteine-mediated decrease in the expression of the cellular isoform of glutathione 
peroxidase (GPx-1) (Weiss et al,2000). This key enzyme for the cellular defence against 
oxidant stress uses glutathione to reduce H2O2 and lipid peroxides to their respective 
alcohols (Flohe, 1989). H202 decomposes to the toxic oxygen species hydroxyl radical, 
which is highly reactive and causes lipid peroxidation, and hydroxide, which promotes 
tissue damage.
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Chapter 5 Discussion
The interaction between circulating dietary constituents and the vascular endothelial 
monolayer is vital to the proper maintenance of vascular homeostatic mechanisms, such 
as vasoregulation. Endothelial dysfunction and subsequent loss of vasoregulatory 
function are implicated in the early stages of atherosclerosis. This study was carried out 
to determine whether the dietary constituents CLA and homocysteine can modulate 
normal endothelial function, with particular focus on eNOS and Cox I expression and 
activity.
Conjugated linoleic acid (CLA) is the collective term used for positional and 
geometrical isomers deriving from the essential fatty acid, linoleic acid. It has been 
postulated that CLA elicits atheroprotective effects in vitro by two potential 
mechanisms. Firstly, by modulating endothelium exposure to oxidative stress. CLA has 
been shown to possess antioxidant properties, in studies it was a more potent 
antioxidant than a-tocopherol (Ha et al, 1990). It has also been shown that CLA may be 
auto oxidised to several furan derivatives that possess a redox buffering capacity 
(Yurawecz et al, 1995). A factor in the aetiology of atherosclerosis (and diabetes) is that 
nitric oxide availability is impaired through increases in oxidative stress (Drexler et al, 
1999). The hypothesis for this study was that the redox-buffering property of CLA may 
modulate the expression and/or activity of eNOS, through regulation of oxidative stress 
with subsequent impact on nitric oxide availability. Secondly, it has been shown that 
isomers and metabolites of CLA are readily incorporated into the phospholipid and 
neutral lipid fraction of the cell membrane (Ha et al, 1990) and may possibly exert its 
effects through altering eicosanoid synthesis. This has previously been proven for a 
venous cell type although no data was presented for the effect of CLA on Cox steady 
state mRNA levels or protein expression (Urquhart et al, 2001). It was therefore 
hypothesised that CLA would putatively affect expression and/or activity of eNOS 
and/or Cox I in BAEC.
The results from this study suggest that CLA downregulates endothelial release of 
prostacyclin (PGI2) and probably many other prostanoids (PGE2 and PGD2). This effect 
on prostanoid production can be viewed in two ways. In one regard it would seem that
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CLA is pro-atherogenic. Prostacyclin and other prostaglandin’s are potent vasodilator, 
in balance with thromboxane, and also inhibits platelets aggregation. On the other hand 
a decrease in the production of prostaglandin’s by the vascular endothelium may 
attenuate any pro-inflammatory pathogenicity and inhibit atherosclerotic plaque 
formation. In an animal study, carried out recently by Sinead Toomey et al, (2003) at 
the Royal College of Surgeons in Ireland, it was suggested that a CLA-supplemented 
diet resulted in a profound resolution of atherosclerotic lesion mediated by inhibition of 
prostaglandin formation and activation of PPARy nuclear receptor. Based on the 
findings from other animal studies reviewed, it is most likely that CLAs effects are 
beneficial, and mediated, in part at least, by prostanoid downregulation.
There is also the possibility that CLA modulates the lipooxygenase and epoxygenase 
pathways. Arachidonic acid is also the natural substrate for these pathways. The 
possibility that CLA exerts its effects through all three eicosanoid pathways 
(Cyclooxygenase, Lipoxygenase and Epoxygenase) would be highly significant and 
could explain how CLA exerts many of its physiological roles in atherosclerosis, 
carcinogensis, diabetes, obesity and immunity.
CLA treatment also had no impact on basal levels of eNOS activity over an acute and 
chronic time course. Subsequently it was decided to examine whether CLA affected 
agonist-stimulated eNOS activity. Pre-treatment with CLA was shown to synergistically 
augment agonist activation of eNOS. The overall effect therefore suggests that CLA 
may be atheroprotective through a potentiation of agonist mediated production of nitric 
oxide. The endothelial vasodilator function, mediated in part by nitric oxide, is impaired 
in the early stages of atherosclerosis. CLA may protect against this vasodilatory loss. 
An increased level of nitric oxide may also protect against other early stage 
atherosclerotic events such as endothelium adhesion of leucocytes and platelets (Kubes 
et al, 1991) and vascular smooth muscle cell proliferation (Garg and Hassid, 1989).
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It is also possible that the observed effects on nitric oxide and PGI2 may be related. 
Endothelial cells release PGI2 and nitric oxide in a coupled manner (Gryglewski et al, 
1986). Nitric oxide has also been shown to highly stimulate prostaglandin production 
(Davidge et al, 1995). This suggests that CLAs inhibitory action against Cox in non­
stimulated BAEC may be reversed in agonist stimulated BAEC, where nitric oxide may 
mediate Cox activation.
It was expected in this study that homocysteines induced oxidant stress may modulate 
nitric oxide breakdown to nitrite, however none was observed. Potential direction for 
further studies could include examining the specific role of reduced homocysteine, the 
most potent form of homocysteine, on vascular oxidant stress. Of the may forms of 
homocysteine present in blood plasma, reduced homocysteine has been shown to be the 
most deleterious to flow mediated vasodilatation (Chambers et al, 2001).
Treatment of non-stimulated BAEC resulted in a lack of modulation of nitrite levels. 
Because of this the effect of homocysteine on stimulated BAEC could also be 
examined. Bradykinin, calcium ionophore or acetylcholine would be suitable treatments 
for stimulation of eNOS (Venema, 2Q02; Taniguchi, 1999; Figueroa, 2002), although 
the physiologically predominant endothelial stimulators are haemodynamic forces such 
as shear stress and cyclic strain (Awolesi, 1994). The CELLMAX™ QUAD perfused 
capillary co-culture system could be used to expose endothelial cells to physiologically 
relevant shear stress (Redmond et al, 1995).
This would also be a suitable model for examining subsequent alteration of vascular 
smooth muscle cell metabolism resulting from treatment of shear-stimulated endothelial 
cells. Previous reports have demonstrated that homocysteine induces DNA synthesis 
and proliferation (Taha, 1999; Chen, C., 2000) of vascular smooth muscle cells. It has 
been suggested this is mediated via MAP kinase activation (Woo, 2000) and a hydrogen 
peroxide-independent mechanism (Taha, 1999). Homocysteine also induces a release of 
intracellular Ca2+ from vascular smooth muscle cells and may induce vascular reactivity 
(Mujumdar, 2000). A problem with some of these in vitro studies may be that 
homocysteine is directly presented to vascular smooth muscle cells. The physiological
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reality is that circulating homocysteine would primary influence endothelial cell 
function. It may prove interesting to investigate the subsequent effects of homocysteine 
induced endothelial dysfunction on vascular smooth muscle cell metabolism. The 
CELLMAX™ QUAD perfused capillary co-culture system would again be a suitable in 
vitro model for such studies.
In conclusion while homocysteine does not appear to modulate eNOS expression or 
activity under basal conditions this study does however suggest two possible 
mechanisms of action for the anti-atherogenic effects of CLA previously observed in 
animal models. These mechanisms centre on the ability of CLA to modulate the activity 
of two enzymatic pathways, endothelial nitric oxide synthase and cycloxygenase. CLA 
isomer mix does appear to putatively modulate prostanoid production and agonist- 
stimulated nitric oxide release from BAEC.
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